Cancer types

cancer statistic est. 2026

Rank	Cancer Type / Subtype / Histology / Pathological Entity	Est. Monthly Global Search Volume	Est. Annual New Cases (Worldwide)	Est. Annual Deaths (Worldwide)	5-Year Relative Survival Rate (%)
1	Invasive Breast Cancer (Invasive Ductal & Lobular Carcinoma)	24 500 000	2 430 000	695 000	91,2%
2	Lung & Bronchus Cancer (Non-Small Cell & Small Cell) (Lung cancer)	16 500 000	2 600 000	1 900 000	25,4%
3	Colorectal Adenocarcinoma (Colon cancer & Rectal)	11 200 000	2 030 000	935 000	65,0%
4	Prostate Adenocarcinoma (Prostate cancer)	9 800 000	1 546 000	397 000	97,1%
5	Cutaneous Melanoma (Skin cancer)	8 200 000	338 000	58 000	94,1%
6	Cervical Squamous Cell & Adenocarcinoma (Cervical cancer)	7 400 000	604 000	342 000	67,2%
7	Thyroid Carcinoma (Papillary, Follicular, Medullary) (Thyroid cancer)	6 100 000	959 000	44 000	98,5%
8	Glioblastoma Multiforme & High-Grade Gliomas	5 500 000	324 000	252 000	35,9%
9	Pancreatic Ductocarcinoma (Adenocarcinoma) (Pancreatic cancer)	5 200 000	531 000	491 000	12,8%
10	Leukemia (Acute & Chronic Lineages)	4 900 000	495 000	305 000	66,7%
11	Stomach (Gastric) Adenocarcinoma (Stomach cancer)	4 500 000	980 000	660 000	35,7%
12	High-Grade Serous Ovarian Carcinoma (Ovarian cancer)	4 100 000	331 000	207 000	50,8%
13	Hepatocellular Carcinoma & Intrahepatic Bile Duct Cancer	3 800 000	843 000	755 000	21,6%
14	Clear Cell Renal Cell Carcinoma (Kidney)	3 400 000	431 000	156 000	77,6%
15	Non-Hodgkin Lymphoma (DLBCL, Follicular, Marginal Zone)	3 100 000	563 000	242 000	74,3%
16	Urothelial Bladder Carcinoma (Bladder cancer)	2 900 000	442 000	150 000	77,9%
17	Uterine Endometrial Adenocarcinoma (Uterine cancer)	2 800 000	420 000	97 000	81,3%
18	Esophageal Squamous Cell & Adenocarcinoma (Esophageal cancer)	2 200 000	494 000	445 000	21,7%
19	Classical Hodgkin Lymphoma	2 100 000	83 000	23 000	88,9%
20	Multiple Myeloma (Plasma Cell Myeloma)	1 900 000	196 000	121 000	59,8%
21	Lip & Oral Cavity Squamous Cell Carcinoma	1 800 000	452 000	202 000	68,5%
22	Acute Myeloid Leukemia (AML)	1 600 000	165 000	115 000	31,7%
23	HPV-Positive Oropharyngeal Carcinoma	1 400 000	98 000	48 000	68,0%
24	Diffuse Large B-Cell Lymphoma (DLBCL) – Germinal Center B-cell (GCB)	1 372 404	97 462	17 848	59,7%
25	Diffuse Large B-Cell Lymphoma (DLBCL) – Activated B-cell (ABC)	1 360 052	96 292	37 675	84,3%
26	Follicular Lymphoma Grade 1	1 347 812	95 137	16 591	40,4%
27	Follicular Lymphoma Grade 2	1 335 682	93 995	41 221	63,4%
28	Follicular Lymphoma Grade 3A	1 323 660	92 867	49 701	62,8%
29	Follicular Lymphoma Grade 3B	1 311 748	91 753	46 535	78,0%
30	Anal cancer Squamous Cell Carcinoma	1 300 000	50 000	19 000	70,2%
31	Mantle Cell Lymphoma – Classical Variant	1 299 942	90 652	46 961	65,5%
32	Mantle Cell Lymphoma – Blastoid Variant	1 288 242	89 564	22 137	67,4%
33	Extranodal Marginal Zone Lymphoma of MALT	1 276 648	88 489	15 812	81,4%
34	Nodal Marginal Zone B-Cell Lymphoma	1 265 158	87 427	31 326	81,2%
35	Splenic Marginal Zone Lymphoma	1 253 772	86 378	41 733	71,9%
36	Burkitt Lymphoma – Endemic Variant	1 242 488	85 341	19 749	42,4%
37	Burkitt Lymphoma – Sporadic Variant	1 231 305	84 317	53 908	89,1%
38	Burkitt Lymphoma – Immunodeficiency-Associated	1 220 224	83 306	45 545	94,0%
39	Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)	1 209 242	82 306	32 280	30,3%
40	Laryngeal Squamous Cell Carcinoma	1 200 000	184 000	99 000	61,1%
41	Angioimmunoblastic T-Cell Lymphoma (AITL)	1 198 359	81 318	24 428	63,5%
42	Anaplastic Large Cell Lymphoma (ALK-Positive)	1 187 573	80 342	22 079	56,6%
43	Anaplastic Large Cell Lymphoma (ALK-Negative)	1 176 885	79 378	46 398	73,6%
44	Adult T-Cell Leukemia/Lymphoma (HTLV-1 Associated)	1 166 293	78 426	33 412	26,7%
45	Cutaneous T-Cell Lymphoma – Mycosis Fungoides Stage IA-IIA	1 155 797	77 485	38 491	50,1%
46	Cutaneous T-Cell Lymphoma – Mycosis Fungoides Stage IIB-IVB	1 145 394	76 555	26 317	52,5%
47	Sézary Syndrome	1 135 086	75 636	32 556	59,4%
48	Primary Central Nervous System Lymphoma	1 124 870	74 728	13 579	59,9%
49	Primary Mediastinal (Thymic) Large B-Cell Lymphoma	1 114 746	73 832	38 213	66,4%
50	Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia	1 104 713	72 946	27 737	88,3%
51	Chronic Lymphocytic Leukemia (CLL)	1 100 000	135 000	48 000	87,9%
52	Hairy Cell Leukemia – Classical	1 094 771	72 070	18 527	54,0%
53	Hairy Cell Leukemia – Variant	1 084 918	71 206	43 499	58,1%
54	T-Cell Prolymphocytic Leukemia	1 075 154	70 351	27 755	26,8%
55	B-Cell Prolymphocytic Leukemia	1 065 477	69 507	16 612	33,9%
56	Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL)	1 055 888	68 673	10 020	73,6%
57	Precursor T-Cell Acute Lymphoblastic Leukemia (T-ALL)	1 046 385	67 849	40 032	32,1%
58	Ph-Positive Acute Lymphoblastic Leukemia	1 036 968	67 035	30 153	57,4%
59	Chronic Myeloid Leukemia (CML) – Chronic Phase	1 027 635	66 230	24 870	40,8%
60	Chronic Myeloid Leukemia (CML) – Accelerated Phase	1 018 386	65 435	38 576	68,2%
61	Chronic Myeloid Leukemia (CML) – Blast Crisis	1 009 221	64 650	23 409	57,4%
62	Myelodysplastic Syndrome (MDS) – Single Lineage Dysplasia	1 000 138	63 874	39 130	93,1%
63	Myelodysplastic Syndrome (MDS) – Multilineage Dysplasia	991 137	63 108	25 822	63,6%
64	Myelodysplastic Syndrome (MDS) with Excess Blasts-1	982 216	62 350	29 614	46,2%
65	Myelodysplastic Syndrome (MDS) with Excess Blasts-2	973 376	61 602	33 505	59,6%
66	Myelodysplastic Syndrome (MDS) with Isolated del(5q)	964 616	60 863	22 751	86,0%
67	Polycythemia Vera (JAK2 V617F Positive)	955 934	60 133	21 018	45,3%
68	Gallbladder Adenocarcinoma	950 000	115 000	84 000	20,0%
69	Essential Thrombocythemia (CALR/MPL/JAK2 Mutated)	947 331	59 411	15 600	27,3%
70	Primary Myelofibrosis – Prefibrotic Stage	938 805	58 698	27 440	66,2%
71	Primary Myelofibrosis – Overt Fibrotic Stage	930 356	57 994	21 043	61,1%
72	Chronic Myelomonocytic Leukemia-1 (CMML-1)	921 983	57 298	21 741	88,6%
73	Chronic Myelomonocytic Leukemia-2 (CMML-2)	913 685	56 610	14 597	58,5%
74	Juvenile Myelomonocytic Leukemia (JMML)	905 462	55 931	21 867	82,0%
75	Atypical Chronic Myeloid Leukemia (BCR-ABL1 Negative)	897 312	55 260	30 294	63,5%
76	Systemic Mastocytosis with Associated Hematologic Neoplasm	889 237	54 597	32 804	82,4%
77	Aggressive Systemic Mastocytosis	881 233	53 941	15 525	88,3%
78	Solitary Plasmacytoma of Bone (Bone cancer)	873 302	53 294	9 173	72,6%
79	Extramedullary Plasmacytoma	865 443	52 655	28 228	60,5%
80	Plasma Cell Leukemia	857 654	52 023	18 730	91,6%
81	Nasopharyngeal Carcinoma	850 000	133 000	80 000	62,4%
82	AL Amyloidosis with Renal & Cardiac Involvement	849 935	51 398	32 517	83,1%
83	POEMS Syndrome	842 285	50 782	18 989	29,4%
84	Glioblastoma IDH-Wildtype	695 587	34 045	9 754	51,9%
85	Glioblastoma IDH-Mutant	689 327	33 637	5 639	73,8%
86	Anaplastic Astrocytoma IDH-Mutant	683 123	33 233	12 891	47,5%
87	Small Intestine Adenocarcinoma (Bowel cancer)	680 000	111 000	41 000	69,1%
88	Diffuse Midline Glioma (H3 K27M-Mutant)	676 975	32 834	3 605	8,0%
89	Diffuse Hemispheric Glioma (H3 G34R/V-Mutant)	670 882	32 440	16 429	90,0%
90	Oligodendroglioma 1p/19q Codeleted Grade 2	664 844	32 051	5 068	77,9%
91	Oligodendroglioma 1p/19q Codeleted Grade 3	658 861	31 666	8 660	62,7%
92	Ependymoma RELA Fusion-Positive	652 931	31 286	19 594	92,2%
93	Posterior Fossa Ependymoma Group PFA	647 054	30 911	17 555	63,9%
94	Posterior Fossa Ependymoma Group PFB	641 231	30 540	6 362	35,6%
95	Medulloblastoma WNT-Activated	635 460	30 174	15 332	75,7%
96	Medulloblastoma SHH-Activated (TP53-Wildtype)	629 741	29 811	22 804	51,3%
97	Medulloblastoma SHH-Activated (TP53-Mutant)	624 073	29 454	17 799	19,9%
98	Medulloblastoma Non-WNT/Non-SHH Group 3	618 456	29 100	7 451	59,7%
99	Medulloblastoma Non-WNT/Non-SHH Group 4	612 890	28 751	22 161	85,1%
100	Atypical Teratoid/Rhabdoid Tumor (ATRT)	607 374	28 406	12 876	15,4%
101	Embryonal Tumor with Multilayered Rosettes (ETMR)	601 908	28 065	15 940	90,3%
102	Craniopharyngioma – Adamantinomatous	596 491	27 728	17 979	88,5%
103	Craniopharyngioma – Papillary	591 122	27 396	8 607	44,3%
104	Pituitary Neuroendocrine Tumor (PitNET) / Carcinoma	585 802	27 067	18 015	53,8%
105	Pineoblastoma	580 530	26 742	6 356	9,2%
106	Retinoblastoma – Bilateral Heritable	575 305	26 421	4 605	86,1%
107	Retinoblastoma – Unilateral Non-Heritable	570 127	26 104	3 549	38,5%
108	Neuroblastoma – High-Risk MYCN-Amplified	564 996	25 791	8 959	75,7%
109	Neuroblastoma – Low/Intermediate Risk	559 911	25 481	3 008	52,9%
110	Wilms Tumor (Nephroblastoma) – Favorable Histology	554 872	25 176	8 293	34,7%
111	Wilms Tumor (Nephroblastoma) – Focal Anaplasia	549 878	24 873	8 164	18,7%
112	Wilms Tumor (Nephroblastoma) – Diffuse Anaplasia	544 929	24 575	18 778	58,3%
113	Hepatoblastoma – Epithelial Type	540 025	24 280	16 108	21,5%
114	Hepatoblastoma – Mixed Epithelial/Mesenchymal	535 165	23 989	11 124	46,2%
115	Pleuropulmonary Blastoma (Type I, II, III)	530 348	23 701	7 951	60,6%
116	Malignant Rhabdoid Tumor of Kidney (Kidney cancer)	525 575	23 416	13 463	14,1%
117	Desmoplastic Small Round Cell Tumor (DSRCT)	520 845	23 135	8 777	25,2%
118	Clear Cell Sarcoma of Kidney (Kidney cancer)	516 157	22 858	17 029	12,0%
119	Infantile Fibrosarcoma (NTRK Fusion-Positive)	511 512	22 583	10 870	81,8%
120	Pancreatoblastoma (Pancreatic cancer)	506 908	22 312	9 287	74,4%
121	Adrenocortical Carcinoma – Pediatric Type	502 346	22 045	5 113	70,6%
122	Adrenocortical Carcinoma – Adult Type	497 825	21 780	15 561	19,4%
123	Malignant Pheochromocytoma (SDHB-Mutated)	493 345	21 519	10 134	77,1%
124	Malignant Extra-Adrenal Paraganglioma	488 904	21 261	9 818	92,2%
125	Thymoma Type A	484 504	21 005	4 458	82,3%
126	Thymoma Type AB	480 144	20 753	7 740	45,4%
127	Thymoma Type B1	475 822	20 504	7 993	14,9%
128	Thymoma Type B2	471 540	20 258	6 349	38,3%
129	Thymoma Type B3	467 296	20 015	5 692	51,8%
130	Thymic Squamous Cell Carcinoma	463 091	19 775	12 778	44,6%
131	Thymic Neuroendocrine Carcinoma	458 923	19 538	8 350	36,7%
132	Malignant Pleural Mesothelioma – Epithelioid Subtype	454 792	19 303	8 443	18,6%
133	Malignant Pleural Mesothelioma – Sarcomatoid Subtype	450 699	19 072	12 542	78,1%
134	Malignant Pleural Mesothelioma – Biphasic Subtype	446 643	18 843	12 649	82,6%
135	Malignant Peritoneal Mesothelioma	442 623	18 617	4 876	91,9%
136	Tunica Vaginalis Mesothelioma (Vaginal cancer)	438 640	18 393	13 151	64,8%
137	Merkel Cell Carcinoma (Polyomavirus-Positive)	434 692	18 172	7 007	76,9%
138	Merkel Cell Carcinoma (Polyomavirus-Negative / UV-Driven)	430 780	17 954	12 471	67,0%
139	Kaposi Sarcoma – Epidemic (HIV-Associated)	426 903	17 739	13 709	39,0%
140	Kaposi Sarcoma – Classic Mediterranean	423 060	17 526	3 675	57,5%
141	Hypopharyngeal Carcinoma	420 000	84 000	38 000	37,5%
142	Kaposi Sarcoma – Endemic African	419 253	17 316	8 668	55,4%
143	Extramammary Paget Disease	415 480	17 108	3 024	71,0%
144	Sebaceous Carcinoma of Eyelid (Eye cancer)	411 740	16 903	8 266	58,0%
145	Microcystic Adnexal Carcinoma	408 035	16 700	4 176	33,9%
146	Trichilemmal Carcinoma	404 362	16 499	4 746	56,9%
147	Dermatofibrosarcoma Protuberans (DFSP)	400 723	16 301	2 787	31,2%
148	DFSP with Fibrosarcomatous Transformation	397 116	16 106	12 376	23,1%
149	Giant Cell Tumor of Bone (Malignant Transformation)	393 542	15 912	9 215	74,8%
150	Adamantinoma of Long Bones	390 001	15 722	9 522	24,3%
151	Angiosarcoma of Liver (Liver cancer)	386 491	15 533	8 404	52,6%
152	Clear Cell Sarcoma of Soft Tissue (Melanoma of Soft Parts)	383 012	15 346	4 507	81,7%
153	Alveolar Soft Part Sarcoma	379 565	15 162	4 605	35,7%
154	Epithelioid Hemangioendothelioma (WWTR1-CAMTA1 Fusion)	376 149	14 980	4 233	13,5%
155	Lung Adenocarcinoma (Stage I / Early Localized)	348 320	17 018	5 844	88,2%
156	Adenocarcinoma of the Breast – Stage I / Early Localized	345 533	16 847	9 723	46,6%
157	Stage I / Early Localized Colon Adenocarcinoma (Colon cancer)	342 769	16 679	1 499	19,3%
158	Rectum Adenocarcinoma (Stage I / Early Localized)	340 027	16 512	1 563	21,6%
159	Adenocarcinoma of the Stomach – Stage I / Early Localized	337 307	16 347	8 482	60,6%
160	Stage I / Early Localized Pancreas Adenocarcinoma	334 608	16 184	10 990	41,1%
161	Liver Adenocarcinoma (Stage I / Early Localized)	331 931	16 022	9 277	63,2%
162	Adenocarcinoma of the Kidney – Stage I / Early Localized (Kidney cancer)	329 276	15 861	7 914	63,9%
163	Stage I / Early Localized Bladder Adenocarcinoma	326 642	15 703	10 549	38,2%
164	Prostate Adenocarcinoma (Stage I / Early Localized)	324 028	15 546	3 389	50,8%
165	Adenocarcinoma of the Ovary – Stage I / Early Localized	321 436	15 390	10 875	86,5%
166	Stage I / Early Localized Uterus Adenocarcinoma	318 865	15 236	7 912	85,1%
167	Cervix Adenocarcinoma (Stage I / Early Localized)	316 314	15 084	7 784	90,4%
168	Adenocarcinoma of the Thyroid – Stage I / Early Localized	313 783	14 933	4 912	92,4%
169	Stage I / Early Localized Brain Adenocarcinoma (Brain cancer)	311 273	14 784	4 554	74,2%
170	Esophagus Adenocarcinoma (Stage I / Early Localized)	308 783	14 636	5 261	13,0%
171	Adenocarcinoma of the Larynx – Stage I / Early Localized	306 313	14 490	7 607	35,9%
172	Stage I / Early Localized Oral Cavity Adenocarcinoma	303 862	14 345	9 945	79,8%
173	Skin Adenocarcinoma (Stage I / Early Localized)	301 431	14 201	2 247	77,0%
174	Adenocarcinoma of the Bone – Stage I / Early Localized	299 020	14 059	3 993	88,7%
175	Stage I / Early Localized Gallbladder Adenocarcinoma	296 628	13 919	5 943	40,5%
176	Bile Duct Adenocarcinoma (Stage I / Early Localized)	294 255	13 779	6 048	73,1%
177	Adenocarcinoma of the Small Intestine – Stage I / Early Localized	291 900	13 642	2 074	64,2%
178	Stage I / Early Localized Anus Adenocarcinoma	289 565	13 505	2 102	21,8%
179	Vagina Adenocarcinoma (Stage I / Early Localized)	287 249	13 370	4 099	66,7%
180	Adenocarcinoma of the Vulva – Stage I / Early Localized (Vulvar cancer)	284 951	13 237	6 614	13,5%
181	Stage I / Early Localized Testis Adenocarcinoma (Testicular cancer)	282 671	13 104	5 896	41,6%
182	Penis Adenocarcinoma (Stage I / Early Localized)	280 410	12 973	4 226	31,6%
183	Adenocarcinoma of the Adrenal Gland – Stage I / Early Localized	278 166	12 843	4 487	29,9%
184	Stage I / Early Localized Parathyroid Adenocarcinoma	275 941	12 715	2 036	57,7%
185	Thymus Adenocarcinoma (Stage I / Early Localized)	273 734	12 588	6 336	91,4%
186	Adenocarcinoma of the Spleen – Stage I / Early Localized	271 544	12 462	6 450	45,1%
187	Stage I / Early Localized Nasopharynx Adenocarcinoma	269 371	12 337	3 000	23,7%
188	Hypopharynx Adenocarcinoma (Stage I / Early Localized)	267 216	12 214	1 159	34,8%
189	Adenocarcinoma of the Oropharynx – Stage I / Early Localized	265 079	12 092	4 673	33,7%
190	Stage I / Early Localized Salivary Gland Adenocarcinoma	262 958	11 971	3 369	92,2%
191	Appendix Adenocarcinoma (Stage I / Early Localized)	260 854	11 851	5 450	83,2%
192	Adenocarcinoma of the Peritoneum – Stage I / Early Localized	258 768	11 733	5 091	66,9%
193	Stage I / Early Localized Retroperitoneum Adenocarcinoma	256 697	11 615	8 075	55,2%
194	Heart / Mediastinum Adenocarcinoma (Stage I / Early Localized)	254 644	11 499	2 871	65,4%
195	Squamous Cell Carcinoma of the Lung – Stage I / Early Localized	252 607	11 384	6 408	38,3%
196	Stage I / Early Localized Breast Squamous Cell Carcinoma	250 586	11 270	5 646	12,0%
197	Colon Squamous Cell Carcinoma (Stage I / Early Localized)	248 581	11 158	7 877	51,5%
198	Squamous Cell Carcinoma of the Rectum – Stage I / Early Localized	246 592	11 046	7 742	69,4%
199	Stage I / Early Localized Stomach Squamous Cell Carcinoma	244 620	10 936	6 908	90,7%
200	Pancreas Squamous Cell Carcinoma (Stage I / Early Localized)	242 663	10 826	7 143	45,3%
201	Squamous Cell Carcinoma of the Liver – Stage I / Early Localized	240 721	10 718	7 553	92,8%
202	Stage I / Early Localized Kidney Squamous Cell Carcinoma (Kidney cancer)	238 796	10 611	2 427	82,3%
203	Bladder Squamous Cell Carcinoma (Stage I / Early Localized)	236 885	10 505	3 151	28,3%
204	Squamous Cell Carcinoma of the Prostate – Stage I / Early Localized	234 990	10 400	3 222	65,8%
205	Stage I / Early Localized Ovary Squamous Cell Carcinoma	233 110	10 296	4 439	51,8%
206	Uterus Squamous Cell Carcinoma (Stage I / Early Localized)	231 245	10 193	5 960	60,9%
207	Squamous Cell Carcinoma of the Cervix – Stage I / Early Localized	229 395	10 091	2 020	65,0%
208	Stage I / Early Localized Thyroid Squamous Cell Carcinoma	227 560	9 990	1 782	87,9%
209	Brain Squamous Cell Carcinoma (Stage I / Early Localized)	225 740	9 890	6 807	81,0%
210	Squamous Cell Carcinoma of the Esophagus – Stage I / Early Localized	223 934	9 791	6 015	71,4%
211	Stage I / Early Localized Larynx Squamous Cell Carcinoma	222 142	9 693	5 709	66,0%
212	Oral Cavity Squamous Cell Carcinoma (Stage I / Early Localized)	220 365	9 596	1 284	43,1%
213	Squamous Cell Carcinoma of the Skin – Stage I / Early Localized	218 602	9 500	5 204	22,9%
214	Stage I / Early Localized Bone Squamous Cell Carcinoma	216 853	9 405	5 203	96,9%
215	Gallbladder Squamous Cell Carcinoma (Stage I / Early Localized)	215 119	9 311	854	29,7%
216	Squamous Cell Carcinoma of the Bile Duct – Stage I / Early Localized	213 398	9 218	5 744	61,1%
217	Stage I / Early Localized Small Intestine Squamous Cell Carcinoma	211 691	9 126	4 074	93,2%
218	Anus Squamous Cell Carcinoma (Stage I / Early Localized)	209 997	9 034	2 923	93,8%
219	Squamous Cell Carcinoma of the Vagina – Stage I / Early Localized	208 317	8 944	3 672	66,4%
220	Stage I / Early Localized Vulva Squamous Cell Carcinoma	206 650	8 855	1 604	54,8%
221	Testis Squamous Cell Carcinoma (Stage I / Early Localized)	204 997	8 766	1 181	74,0%
222	Squamous Cell Carcinoma of the Penis – Stage I / Early Localized	203 357	8 678	2 547	33,5%
223	Stage I / Early Localized Adrenal Gland Squamous Cell Carcinoma	201 730	8 592	916	62,0%
224	Parathyroid Squamous Cell Carcinoma (Stage I / Early Localized)	200 117	8 506	4 966	25,0%
225	Squamous Cell Carcinoma of the Thymus – Stage I / Early Localized	198 516	8 421	2 252	57,5%
226	Stage I / Early Localized Spleen Squamous Cell Carcinoma	196 928	8 336	2 572	94,7%
227	Nasopharynx Squamous Cell Carcinoma (Stage I / Early Localized)	195 352	8 253	1 656	75,2%
228	Squamous Cell Carcinoma of the Hypopharynx – Stage I / Early Localized	193 789	8 171	703	63,1%
229	Stage I / Early Localized Oropharynx Squamous Cell Carcinoma	192 239	8 089	3 132	47,3%
230	Salivary Gland Squamous Cell Carcinoma (Stage I / Early Localized)	190 701	8 008	4 802	88,6%
231	Squamous Cell Carcinoma of the Appendix – Stage I / Early Localized	189 175	7 928	5 601	96,7%
232	Stage I / Early Localized Peritoneum Squamous Cell Carcinoma	187 662	7 849	1 486	55,4%
233	Retroperitoneum Squamous Cell Carcinoma (Stage I / Early Localized)	186 161	7 770	1 514	57,4%
234	Squamous Cell Carcinoma of the Heart / Mediastinum – Stage I / Early Localized	184 671	7 692	1 422	87,3%
235	Stage I / Early Localized Lung Small Cell Carcinoma	183 194	7 615	3 119	86,9%
236	Breast Small Cell Carcinoma (Stage I / Early Localized)	181 728	7 539	3 707	11,2%
237	Small Cell Carcinoma of the Colon – Stage I / Early Localized	180 275	7 464	2 386	42,6%
238	Stage I / Early Localized Rectum Small Cell Carcinoma	178 832	7 389	1 613	24,3%
239	Stomach Small Cell Carcinoma (Stage I / Early Localized)	177 402	7 315	3 441	21,9%
240	Small Cell Carcinoma of the Pancreas – Stage I / Early Localized	175 983	7 242	5 144	52,7%
241	Stage I / Early Localized Liver Small Cell Carcinoma	174 575	7 170	4 584	73,5%
242	Kidney Small Cell Carcinoma (Stage I / Early Localized)	173 178	7 098	2 299	64,1%
243	Small Cell Carcinoma of the Bladder – Stage I / Early Localized	171 793	7 027	3 474	40,9%
244	Stage I / Early Localized Prostate Small Cell Carcinoma	170 418	6 957	4 606	21,4%
245	Ovary Small Cell Carcinoma (Stage I / Early Localized)	169 055	6 887	2 838	82,3%
246	Small Cell Carcinoma of the Uterus – Stage I / Early Localized	167 703	6 818	3 528	50,2%
247	Stage I / Early Localized Cervix Small Cell Carcinoma	166 361	6 750	3 068	18,1%
248	Thyroid Small Cell Carcinoma (Stage I / Early Localized)	165 030	6 683	3 866	18,6%
249	Small Cell Carcinoma of the Brain – Stage I / Early Localized	163 710	6 616	2 624	37,8%
250	Stage I / Early Localized Esophagus Small Cell Carcinoma	162 400	6 550	3 681	30,4%
251	Larynx Small Cell Carcinoma (Stage I / Early Localized) Larynx cancer	161 101	6 484	1 867	54,5%
252	Small Cell Carcinoma of the Oral Cavity – Stage I / Early Localized	159 812	6 419	1 876	89,0%
253	Stage I / Early Localized Skin Small Cell Carcinoma	158 534	6 355	3 452	84,7%
254	Bone Small Cell Carcinoma (Stage I / Early Localized)	157 265	6 292	2 126	26,2%
255	Small Cell Carcinoma of the Gallbladder – Stage I / Early Localized	156 007	6 229	3 712	29,9%
256	Stage I / Early Localized Bile Duct Small Cell Carcinoma	154 759	6 166	3 212	41,0%
257	Small Intestine Small Cell Carcinoma (Stage I / Early Localized)	153 521	6 105	3 564	46,2%
258	Small Cell Carcinoma of the Anus – Stage I / Early Localized	152 293	6 044	3 590	43,8%
259	Stage I / Early Localized Vagina Small Cell Carcinoma	151 075	5 983	1 069	74,9%
260	Vulva Small Cell Carcinoma (Stage I / Early Localized)	149 866	5 923	2 963	22,0%
261	Small Cell Carcinoma of the Testis – Stage I / Early Localized	148 667	5 864	1 473	82,9%
262	Stage I / Early Localized Penis Small Cell Carcinoma	147 478	5 805	1 653	83,3%
263	Adrenal Gland Small Cell Carcinoma (Stage I / Early Localized)	146 298	5 747	2 094	23,5%
264	Small Cell Carcinoma of the Parathyroid – Stage I / Early Localized	145 127	5 690	2 738	31,1%
265	Stage I / Early Localized Thymus Small Cell Carcinoma	143 966	5 633	3 955	59,3%
266	Spleen Small Cell Carcinoma (Stage I / Early Localized)	142 815	5 577	886	36,2%
267	Small Cell Carcinoma of the Nasopharynx – Stage I / Early Localized	141 672	5 521	2 060	45,5%
268	Stage I / Early Localized Hypopharynx Small Cell Carcinoma	140 539	5 466	513	72,6%
269	Oropharynx Small Cell Carcinoma (Stage I / Early Localized)	139 414	5 411	2 767	40,0%
270	Small Cell Carcinoma of the Salivary Gland – Stage I / Early Localized	138 299	5 357	2 757	90,4%
271	Stage I / Early Localized Appendix Small Cell Carcinoma	137 193	5 303	3 507	83,9%
272	Peritoneum Small Cell Carcinoma (Stage I / Early Localized)	136 095	5 250	3 621	68,4%
273	Small Cell Carcinoma of the Retroperitoneum – Stage I / Early Localized	135 006	5 198	2 233	29,1%
274	Stage I / Early Localized Heart / Mediastinum Small Cell Carcinoma	133 926	5 146	1 571	39,4%
275	Lung Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	132 855	5 094	3 416	73,3%
276	Large Cell Neuroendocrine Carcinoma of the Breast – Stage I / Early Localized	131 792	5 043	437	59,1%
277	Stage I / Early Localized Colon Large Cell Neuroendocrine Carcinoma	130 738	4 993	1 205	39,7%
278	Rectum Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	129 692	4 943	2 433	46,7%
279	Large Cell Neuroendocrine Carcinoma of the Stomach – Stage I / Early Localized	128 654	4 894	2 828	51,9%
280	Stage I / Early Localized Pancreas Large Cell Neuroendocrine Carcinoma	127 625	4 845	3 144	40,1%
281	Liver Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	126 604	4 796	498	29,9%
282	Large Cell Neuroendocrine Carcinoma of the Kidney – Stage I / Early Localized	125 591	4 748	747	84,3%
283	Stage I / Early Localized Bladder Large Cell Neuroendocrine Carcinoma	124 587	4 701	1 184	12,5%
284	Prostate Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	123 590	4 654	995	50,3%
285	Large Cell Neuroendocrine Carcinoma of the Ovary – Stage I / Early Localized	122 601	4 607	1 185	65,2%
286	Stage I / Early Localized Uterus Large Cell Neuroendocrine Carcinoma	121 620	4 561	595	70,5%
287	Cervix Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	120 647	4 516	1 919	12,0%
288	Large Cell Neuroendocrine Carcinoma of the Thyroid – Stage I / Early Localized	119 682	4 470	631	39,4%
289	Stage I / Early Localized Brain Large Cell Neuroendocrine Carcinoma	118 725	4 426	975	50,9%
290	Esophagus Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	117 775	4 381	2 049	25,7%
291	Large Cell Neuroendocrine Carcinoma of the Larynx – Stage I / Early Localized	116 833	4 338	1 206	59,8%
292	Stage I / Early Localized Oral Cavity Large Cell Neuroendocrine Carcinoma	115 898	4 294	2 299	69,6%
293	Skin Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	114 971	4 251	1 861	20,3%
294	Large Cell Neuroendocrine Carcinoma of the Bone – Stage I / Early Localized	114 051	4 209	1 066	47,1%
295	Stage I / Early Localized Gallbladder Large Cell Neuroendocrine Carcinoma	113 139	4 167	827	74,1%
296	Bile Duct Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	112 234	4 125	2 939	96,0%
297	Large Cell Neuroendocrine Carcinoma of the Small Intestine – Stage I / Early Localized	111 336	4 084	2 706	67,6%
298	Stage I / Early Localized Anus Large Cell Neuroendocrine Carcinoma	110 445	4 043	1 206	40,9%
299	Vagina Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	109 561	4 002	1 873	33,0%
300	Large Cell Neuroendocrine Carcinoma of the Vulva – Stage I / Early Localized	108 685	3 962	2 556	83,2%
301	Stage I / Early Localized Testis Large Cell Neuroendocrine Carcinoma	107 815	3 923	406	53,1%
302	Penis Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	106 953	3 884	364	80,6%
303	Large Cell Neuroendocrine Carcinoma of the Adrenal Gland – Stage I / Early Localized	106 097	3 845	932	75,9%
304	Stage I / Early Localized Parathyroid Large Cell Neuroendocrine Carcinoma	105 248	3 806	788	34,5%
305	Thymus Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	104 406	3 768	2 332	45,4%
306	Large Cell Neuroendocrine Carcinoma of the Spleen – Stage I / Early Localized	103 571	3 730	819	15,7%
307	Stage I / Early Localized Nasopharynx Large Cell Neuroendocrine Carcinoma	102 743	3 693	1 266	16,6%
308	Hypopharynx Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	101 921	3 656	1 981	67,9%
309	Large Cell Neuroendocrine Carcinoma of the Oropharynx – Stage I / Early Localized	101 105	3 620	1 869	76,9%
310	Stage I / Early Localized Salivary Gland Large Cell Neuroendocrine Carcinoma	100 296	3 583	971	52,5%
311	Appendix Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	99 494	3 548	489	54,8%
312	Large Cell Neuroendocrine Carcinoma of the Peritoneum – Stage I / Early Localized	98 698	3 512	1 455	39,0%
313	Stage I / Early Localized Retroperitoneum Large Cell Neuroendocrine Carcinoma	97 909	3 477	985	40,2%
314	Heart / Mediastinum Large Cell Neuroendocrine Carcinoma (Stage I / Early Localized)	97 125	3 442	674	96,0%
315	Mucinous Carcinoma of the Lung – Stage I / Early Localized	96 348	3 408	2 156	26,0%
316	Stage I / Early Localized Breast Mucinous Carcinoma	95 578	3 374	825	92,5%
317	Colon Mucinous Carcinoma (Stage I / Early Localized)	94 813	3 340	2 130	55,8%
318	Mucinous Carcinoma of the Rectum – Stage I / Early Localized	94 054	3 307	1 074	20,1%
319	Stage I / Early Localized Stomach Mucinous Carcinoma	93 302	3 274	1 538	29,5%
320	Pancreas Mucinous Carcinoma (Stage I / Early Localized)	92 556	3 241	1 221	29,0%
321	Mucinous Carcinoma of the Liver – Stage I / Early Localized	91 815	3 208	1 299	56,3%
322	Stage I / Early Localized Kidney Mucinous Carcinoma	91 081	3 176	1 298	79,1%
323	Bladder Mucinous Carcinoma (Stage I / Early Localized)	90 352	3 145	796	86,1%
324	Mucinous Carcinoma of the Prostate – Stage I / Early Localized	89 629	3 113	1 222	59,1%
325	Stage I / Early Localized Ovary Mucinous Carcinoma	88 912	3 082	1 904	39,0%
326	Uterus Mucinous Carcinoma (Stage I / Early Localized)	88 201	3 051	2 191	44,7%
327	Mucinous Carcinoma of the Cervix – Stage I / Early Localized	87 495	3 021	1 431	57,4%
328	Stage I / Early Localized Thyroid Mucinous Carcinoma	86 795	2 990	530	58,4%
329	Brain Mucinous Carcinoma (Stage I / Early Localized)	86 101	2 960	2 092	73,7%
330	Mucinous Carcinoma of the Esophagus – Stage I / Early Localized	85 412	2 931	480	81,2%
331	Stage I / Early Localized Larynx Mucinous Carcinoma	84 729	2 902	1 452	16,3%
332	Oral Cavity Mucinous Carcinoma (Stage I / Early Localized)	84 051	2 873	1 455	14,0%
333	Mucinous Carcinoma of the Skin – Stage I / Early Localized	83 378	2 844	1 664	91,9%
334	Stage I / Early Localized Bone Mucinous Carcinoma	82 711	2 815	547	34,0%
335	Gallbladder Mucinous Carcinoma (Stage I / Early Localized)	82 050	2 787	1 186	41,7%
336	Mucinous Carcinoma of the Bile Duct – Stage I / Early Localized	81 393	2 759	1 028	27,0%
337	Stage I / Early Localized Small Intestine Mucinous Carcinoma	80 742	2 732	312	27,0%
338	Anus Mucinous Carcinoma (Stage I / Early Localized)	80 096	2 704	482	66,1%
339	Mucinous Carcinoma of the Vagina – Stage I / Early Localized	79 455	2 677	1 053	58,0%
340	Stage I / Early Localized Vulva Mucinous Carcinoma	78 820	2 651	261	30,0%
341	Testis Mucinous Carcinoma (Stage I / Early Localized)	78 189	2 624	821	57,7%
342	Mucinous Carcinoma of the Penis – Stage I / Early Localized	77 564	2 598	982	75,3%
343	Stage I / Early Localized Adrenal Gland Mucinous Carcinoma	76 943	2 572	460	38,9%
344	Parathyroid Mucinous Carcinoma (Stage I / Early Localized)	76 328	2 546	1 368	14,5%
345	Mucinous Carcinoma of the Thymus – Stage I / Early Localized	75 717	2 521	213	19,1%
346	Stage I / Early Localized Spleen Mucinous Carcinoma	75 111	2 495	1 135	71,6%
347	Nasopharynx Mucinous Carcinoma (Stage I / Early Localized)	74 510	2 470	1 483	33,1%
348	Mucinous Carcinoma of the Hypopharynx – Stage I / Early Localized	73 914	2 446	1 380	25,1%
349	Stage I / Early Localized Oropharynx Mucinous Carcinoma	73 323	2 421	490	81,2%
350	Salivary Gland Mucinous Carcinoma (Stage I / Early Localized)	72 736	2 397	840	48,2%
351	Mucinous Carcinoma of the Appendix – Stage I / Early Localized	72 155	2 373	1 455	25,7%
352	Stage I / Early Localized Peritoneum Mucinous Carcinoma	71 577	2 349	525	94,2%
353	Retroperitoneum Mucinous Carcinoma (Stage I / Early Localized)	71 005	2 326	502	24,6%
354	Mucinous Carcinoma of the Heart / Mediastinum – Stage I / Early Localized	70 437	2 303	1 646	47,3%
355	Stage I / Early Localized Lung Signet Ring Cell Carcinoma	69 873	2 280	799	84,6%
356	Breast Signet Ring Cell Carcinoma (Stage I / Early Localized)	69 314	2 257	1 198	94,3%
357	Signet Ring Cell Carcinoma of the Colon – Stage I / Early Localized	68 760	2 234	1 078	48,9%
358	Stage I / Early Localized Rectum Signet Ring Cell Carcinoma	68 210	2 212	1 518	63,2%
359	Stomach Signet Ring Cell Carcinoma (Stage I / Early Localized)	67 664	2 190	303	88,1%
360	Signet Ring Cell Carcinoma of the Pancreas – Stage I / Early Localized	67 123	2 168	1 198	21,0%
361	Stage I / Early Localized Liver Signet Ring Cell Carcinoma	66 586	2 146	279	72,5%
362	Kidney Signet Ring Cell Carcinoma (Stage I / Early Localized)	66 053	2 125	1 016	24,6%
363	Signet Ring Cell Carcinoma of the Bladder – Stage I / Early Localized	65 524	2 103	399	66,1%
364	Stage I / Early Localized Prostate Signet Ring Cell Carcinoma	65 000	2 082	418	92,5%
365	Ovary Signet Ring Cell Carcinoma (Stage I / Early Localized)	64 480	2 062	1 462	13,6%
366	Signet Ring Cell Carcinoma of the Uterus – Stage I / Early Localized	63 964	2 041	1 431	66,7%
367	Stage I / Early Localized Cervix Signet Ring Cell Carcinoma	63 453	2 021	1 343	78,9%
368	Thyroid Signet Ring Cell Carcinoma (Stage I / Early Localized)	62 945	2 000	527	42,4%
369	Signet Ring Cell Carcinoma of the Brain – Stage I / Early Localized	62 441	1 980	170	55,8%
370	Stage I / Early Localized Esophagus Signet Ring Cell Carcinoma	61 942	1 960	1 269	83,3%
371	Larynx Signet Ring Cell Carcinoma (Stage I / Early Localized)	61 446	1 941	761	22,9%
372	Signet Ring Cell Carcinoma of the Oral Cavity – Stage I / Early Localized	60 955	1 921	1 129	59,1%
373	Stage I / Early Localized Skin Signet Ring Cell Carcinoma	60 467	1 902	1 332	50,2%
374	Bone Signet Ring Cell Carcinoma (Stage I / Early Localized)	59 983	1 883	884	62,0%
375	Signet Ring Cell Carcinoma of the Gallbladder – Stage I / Early Localized	59 504	1 864	1 259	68,6%
376	Stage I / Early Localized Bile Duct Signet Ring Cell Carcinoma	59 028	1 846	533	32,9%
377	Small Intestine Signet Ring Cell Carcinoma (Stage I / Early Localized)	58 555	1 827	943	50,6%
378	Signet Ring Cell Carcinoma of the Anus – Stage I / Early Localized	58 087	1 809	545	82,0%
379	Stage I / Early Localized Vagina Signet Ring Cell Carcinoma	57 622	1 791	745	56,6%
380	Vulva Signet Ring Cell Carcinoma (Stage I / Early Localized)	57 161	1 773	253	34,7%
381	Signet Ring Cell Carcinoma of the Testis – Stage I / Early Localized	56 704	1 755	182	61,8%
382	Stage I / Early Localized Penis Signet Ring Cell Carcinoma	56 250	1 738	217	90,3%
383	Adrenal Gland Signet Ring Cell Carcinoma (Stage I / Early Localized)	55 800	1 720	758	44,2%
384	Signet Ring Cell Carcinoma of the Parathyroid – Stage I / Early Localized	55 354	1 703	839	60,4%
385	Stage I / Early Localized Thymus Signet Ring Cell Carcinoma	54 911	1 686	627	52,2%
386	Spleen Signet Ring Cell Carcinoma (Stage I / Early Localized)	54 472	1 669	156	88,2%
387	Signet Ring Cell Carcinoma of the Nasopharynx – Stage I / Early Localized	54 036	1 653	274	20,0%
388	Stage I / Early Localized Hypopharynx Signet Ring Cell Carcinoma	53 604	1 636	227	57,0%
389	Oropharynx Signet Ring Cell Carcinoma (Stage I / Early Localized)	53 175	1 620	393	94,6%
390	Signet Ring Cell Carcinoma of the Salivary Gland – Stage I / Early Localized	52 749	1 603	896	17,1%
391	Stage I / Early Localized Appendix Signet Ring Cell Carcinoma	52 327	1 587	738	21,3%
392	Peritoneum Signet Ring Cell Carcinoma (Stage I / Early Localized)	51 909	1 571	1 094	88,8%
393	Signet Ring Cell Carcinoma of the Retroperitoneum – Stage I / Early Localized	51 494	1 556	838	37,4%
394	Stage I / Early Localized Heart / Mediastinum Signet Ring Cell Carcinoma	51 082	1 540	587	38,7%
395	Lung Clear Cell Carcinoma (Stage I / Early Localized)	50 673	1 525	997	70,4%
396	Clear Cell Carcinoma of the Breast – Stage I / Early Localized	50 268	1 510	507	55,2%
397	Stage I / Early Localized Colon Clear Cell Carcinoma	49 865	1 494	930	47,0%
398	Rectum Clear Cell Carcinoma (Stage I / Early Localized)	49 466	1 480	581	62,2%
399	Clear Cell Carcinoma of the Stomach – Stage I / Early Localized	49 071	1 465	528	77,1%
400	Stage I / Early Localized Pancreas Clear Cell Carcinoma	48 678	1 450	662	61,8%
401	Liver Clear Cell Carcinoma (Stage I / Early Localized)	48 289	1 436	558	12,4%
402	Clear Cell Carcinoma of the Kidney – Stage I / Early Localized	47 902	1 421	973	44,1%
403	Stage I / Early Localized Bladder Clear Cell Carcinoma	47 519	1 407	143	51,0%
404	Prostate Clear Cell Carcinoma (Stage I / Early Localized)	47 139	1 393	236	31,7%
405	Clear Cell Carcinoma of the Ovary – Stage I / Early Localized	46 762	1 379	570	34,0%
406	Stage I / Early Localized Uterus Clear Cell Carcinoma	46 388	1 365	486	74,2%
407	Cervix Clear Cell Carcinoma (Stage I / Early Localized)	46 017	1 352	130	62,8%
408	Clear Cell Carcinoma of the Thyroid – Stage I / Early Localized	45 649	1 338	552	93,0%
409	Stage I / Early Localized Brain Clear Cell Carcinoma	45 283	1 325	209	42,7%
410	Esophagus Clear Cell Carcinoma (Stage I / Early Localized)	44 921	1 311	286	17,5%
411	Clear Cell Carcinoma of the Larynx – Stage I / Early Localized	44 562	1 298	245	45,9%
412	Stage I / Early Localized Oral Cavity Clear Cell Carcinoma	44 205	1 285	194	20,1%
413	Skin Clear Cell Carcinoma (Stage I / Early Localized)	43 852	1 272	907	45,5%
414	Clear Cell Carcinoma of the Bone – Stage I / Early Localized	43 501	1 260	105	27,9%
415	Stage I / Early Localized Gallbladder Clear Cell Carcinoma	43 153	1 247	309	79,8%
416	Bile Duct Clear Cell Carcinoma (Stage I / Early Localized)	42 808	1 235	513	89,4%
417	Clear Cell Carcinoma of the Small Intestine – Stage I / Early Localized	42 465	1 222	163	25,4%
418	Stage I / Early Localized Anus Clear Cell Carcinoma	42 125	1 210	802	29,8%
419	Vagina Clear Cell Carcinoma (Stage I / Early Localized)	41 788	1 198	741	80,1%
420	Clear Cell Carcinoma of the Vulva – Stage I / Early Localized	41 454	1 186	521	88,3%
421	Stage I / Early Localized Testis Clear Cell Carcinoma	41 122	1 174	506	14,1%
422	Penis Clear Cell Carcinoma (Stage I / Early Localized)	40 793	1 162	806	95,2%
423	Clear Cell Carcinoma of the Adrenal Gland – Stage I / Early Localized	40 467	1 151	603	83,3%
424	Stage I / Early Localized Parathyroid Clear Cell Carcinoma	40 143	1 139	466	91,3%
425	Thymus Clear Cell Carcinoma (Stage I / Early Localized)	39 822	1 128	781	88,6%
426	Clear Cell Carcinoma of the Spleen – Stage I / Early Localized	39 504	1 116	780	66,9%
427	Stage I / Early Localized Nasopharynx Clear Cell Carcinoma	39 188	1 105	775	15,0%
428	Hypopharynx Clear Cell Carcinoma (Stage I / Early Localized)	38 874	1 094	151	67,1%
429	Clear Cell Carcinoma of the Oropharynx – Stage I / Early Localized	38 563	1 083	280	11,6%
430	Stage I / Early Localized Salivary Gland Clear Cell Carcinoma	38 255	1 072	509	14,8%
431	Appendix Clear Cell Carcinoma (Stage I / Early Localized)	37 948	1 062	713	17,1%
432	Clear Cell Carcinoma of the Peritoneum – Stage I / Early Localized	37 645	1 051	555	58,0%
433	Stage I / Early Localized Retroperitoneum Clear Cell Carcinoma	37 344	1 041	448	55,4%
434	Heart / Mediastinum Clear Cell Carcinoma (Stage I / Early Localized)	37 045	1 030	438	53,6%
435	Papillary Carcinoma of the Lung – Stage I / Early Localized	36 749	1 020	116	41,3%
436	Stage I / Early Localized Breast Papillary Carcinoma	36 455	1 010	427	50,9%
437	Colon Papillary Carcinoma (Stage I / Early Localized)	36 163	1 000	235	12,3%
438	Papillary Carcinoma of the Rectum – Stage I / Early Localized	35 874	990	323	18,7%
439	Stage I / Early Localized Stomach Papillary Carcinoma	35 587	980	501	26,3%
440	Pancreas Papillary Carcinoma (Stage I / Early Localized)	35 302	970	224	59,1%
441	Papillary Carcinoma of the Liver – Stage I / Early Localized	35 020	960	386	40,0%
442	Stage I / Early Localized Kidney Papillary Carcinoma	34 739	951	245	66,6%
443	Bladder Papillary Carcinoma (Stage I / Early Localized)	34 461	941	177	18,9%
444	Papillary Carcinoma of the Prostate – Stage I / Early Localized	34 186	932	279	75,3%
445	Stage I / Early Localized Ovary Papillary Carcinoma	33 912	922	150	91,9%
446	Uterus Papillary Carcinoma (Stage I / Early Localized)	33 641	913	577	78,0%
447	Papillary Carcinoma of the Cervix – Stage I / Early Localized	33 372	904	548	51,8%
448	Stage I / Early Localized Thyroid Papillary Carcinoma	33 105	895	468	70,1%
449	Brain Papillary Carcinoma (Stage I / Early Localized)	32 840	886	253	53,6%
450	Papillary Carcinoma of the Esophagus – Stage I / Early Localized	32 577	877	134	11,1%
451	Stage I / Early Localized Larynx Papillary Carcinoma	32 317	868	280	94,1%
452	Oral Cavity Papillary Carcinoma (Stage I / Early Localized)	32 058	860	342	47,0%
453	Papillary Carcinoma of the Skin – Stage I / Early Localized	31 802	851	376	55,1%
454	Stage I / Early Localized Bone Papillary Carcinoma	31 547	843	259	74,9%
455	Gallbladder Papillary Carcinoma (Stage I / Early Localized)	31 295	834	382	66,9%
456	Papillary Carcinoma of the Bile Duct – Stage I / Early Localized	31 045	826	191	43,4%
457	Stage I / Early Localized Small Intestine Papillary Carcinoma	30 796	817	193	37,1%
458	Anus Papillary Carcinoma (Stage I / Early Localized)	30 550	809	414	69,5%
459	Papillary Carcinoma of the Vagina – Stage I / Early Localized	30 305	801	354	37,4%
460	Stage I / Early Localized Vulva Papillary Carcinoma	30 063	793	333	94,6%
461	Testis Papillary Carcinoma (Stage I / Early Localized)	29 822	785	234	74,3%
462	Papillary Carcinoma of the Penis – Stage I / Early Localized	29 584	777	417	61,7%
463	Stage I / Early Localized Adrenal Gland Papillary Carcinoma	29 347	770	181	51,5%
464	Parathyroid Papillary Carcinoma (Stage I / Early Localized)	29 112	762	520	63,2%
465	Papillary Carcinoma of the Thymus – Stage I / Early Localized	28 879	754	302	67,9%
466	Stage I / Early Localized Spleen Papillary Carcinoma	28 648	747	113	21,9%
467	Nasopharynx Papillary Carcinoma (Stage I / Early Localized)	28 419	739	349	37,8%
468	Papillary Carcinoma of the Hypopharynx – Stage I / Early Localized	28 192	732	249	32,7%
469	Stage I / Early Localized Oropharynx Papillary Carcinoma	27 966	725	264	36,4%
470	Salivary Gland Papillary Carcinoma (Stage I / Early Localized)	27 743	717	126	65,5%
471	Papillary Carcinoma of the Appendix – Stage I / Early Localized	27 521	710	59	61,5%
472	Stage I / Early Localized Peritoneum Papillary Carcinoma	27 301	703	99	82,5%
473	Retroperitoneum Papillary Carcinoma (Stage I / Early Localized)	27 082	696	253	16,9%
474	Papillary Carcinoma of the Heart / Mediastinum – Stage I / Early Localized	26 865	689	224	34,5%
475	Stage I / Early Localized Lung Follicular Carcinoma	26 651	682	390	73,6%
476	Breast Follicular Carcinoma (Stage I / Early Localized)	26 437	675	412	32,6%
477	Follicular Carcinoma of the Colon – Stage I / Early Localized	26 226	669	370	46,3%
478	Stage I / Early Localized Rectum Follicular Carcinoma	26 016	662	178	37,9%
479	Stomach Follicular Carcinoma (Stage I / Early Localized)	25 808	655	122	63,7%
480	Follicular Carcinoma of the Pancreas – Stage I / Early Localized	25 601	649	64	29,3%
481	Stage I / Early Localized Liver Follicular Carcinoma	25 397	642	338	72,3%
482	Kidney Follicular Carcinoma (Stage I / Early Localized)	25 193	636	360	45,7%
483	Follicular Carcinoma of the Bladder – Stage I / Early Localized	24 992	629	399	68,2%
484	Stage I / Early Localized Prostate Follicular Carcinoma	24 792	623	115	19,7%
485	Ovary Follicular Carcinoma (Stage I / Early Localized)	24 594	617	201	62,7%
486	Follicular Carcinoma of the Uterus – Stage I / Early Localized	24 397	611	300	44,9%
487	Stage I / Early Localized Cervix Follicular Carcinoma	24 202	605	287	37,0%
488	Thyroid Follicular Carcinoma (Stage I / Early Localized)	24 008	599	256	94,5%
489	Follicular Carcinoma of the Brain – Stage I / Early Localized	23 816	593	310	40,9%
490	Stage I / Early Localized Esophagus Follicular Carcinoma	23 625	587	393	31,9%
491	Larynx Follicular Carcinoma (Stage I / Early Localized)	23 436	581	235	14,2%
492	Follicular Carcinoma of the Oral Cavity – Stage I / Early Localized	23 249	575	274	27,8%
493	Stage I / Early Localized Skin Follicular Carcinoma	23 063	569	107	48,0%
494	Bone Follicular Carcinoma (Stage I / Early Localized)	22 878	563	254	49,3%
495	Follicular Carcinoma of the Gallbladder – Stage I / Early Localized	22 695	558	178	53,7%
496	Stage I / Early Localized Bile Duct Follicular Carcinoma	22 514	552	65	37,4%
497	Small Intestine Follicular Carcinoma (Stage I / Early Localized)	22 334	547	56	62,3%
498	Follicular Carcinoma of the Anus – Stage I / Early Localized	22 155	541	160	36,6%
499	Stage I / Early Localized Vagina Follicular Carcinoma	21 978	536	184	95,6%
500	Vulva Follicular Carcinoma (Stage I / Early Localized)	21 802	530	255	57,0%
501	Follicular Carcinoma of the Testis – Stage I / Early Localized	21 628	525	320	92,4%
502	Stage I / Early Localized Penis Follicular Carcinoma	21 455	520	136	68,2%
503	Adrenal Gland Follicular Carcinoma (Stage I / Early Localized)	21 283	515	356	54,5%
504	Follicular Carcinoma of the Parathyroid – Stage I / Early Localized	21 113	510	312	41,2%
505	Stage I / Early Localized Thymus Follicular Carcinoma	20 944	504	165	30,0%
506	Spleen Follicular Carcinoma (Stage I / Early Localized)	20 776	499	174	47,9%
507	Follicular Carcinoma of the Nasopharynx – Stage I / Early Localized	20 610	494	236	89,2%
508	Stage I / Early Localized Hypopharynx Follicular Carcinoma	20 445	489	306	79,8%
509	Oropharynx Follicular Carcinoma (Stage I / Early Localized)	20 281	485	212	43,5%
510	Follicular Carcinoma of the Salivary Gland – Stage I / Early Localized	20 119	480	303	85,4%
511	Stage I / Early Localized Appendix Follicular Carcinoma	19 958	475	46	31,3%
512	Peritoneum Follicular Carcinoma (Stage I / Early Localized)	19 799	470	90	64,1%
513	Follicular Carcinoma of the Retroperitoneum – Stage I / Early Localized	19 640	465	177	81,0%
514	Stage I / Early Localized Heart / Mediastinum Follicular Carcinoma	19 483	461	165	27,3%
515	Lung Medullary Carcinoma (Stage I / Early Localized)	19 327	456	45	18,3%
516	Medullary Carcinoma of the Breast – Stage I / Early Localized	19 173	452	65	29,7%
517	Stage I / Early Localized Colon Medullary Carcinoma	19 019	447	70	62,7%
518	Rectum Medullary Carcinoma (Stage I / Early Localized)	18 867	443	215	96,4%
519	Medullary Carcinoma of the Stomach – Stage I / Early Localized	18 716	438	210	46,8%
520	Stage I / Early Localized Pancreas Medullary Carcinoma	18 566	434	123	88,2%
521	Liver Medullary Carcinoma (Stage I / Early Localized)	18 418	429	60	16,7%
522	Medullary Carcinoma of the Kidney – Stage I / Early Localized	18 271	425	126	24,0%
523	Stage I / Early Localized Bladder Medullary Carcinoma	18 124	421	202	19,6%
524	Prostate Medullary Carcinoma (Stage I / Early Localized)	17 979	417	61	81,4%
525	Medullary Carcinoma of the Ovary – Stage I / Early Localized	17 835	412	263	58,7%
526	Stage I / Early Localized Uterus Medullary Carcinoma	17 693	408	159	62,1%
527	Cervix Medullary Carcinoma (Stage I / Early Localized)	17 551	404	64	40,8%
528	Medullary Carcinoma of the Thyroid – Stage I / Early Localized	17 411	400	70	51,1%
529	Stage I / Early Localized Brain Medullary Carcinoma	17 272	396	248	19,6%
530	Esophagus Medullary Carcinoma (Stage I / Early Localized)	17 133	392	281	79,4%
531	Medullary Carcinoma of the Larynx – Stage I / Early Localized	16 996	388	136	92,5%
532	Stage I / Early Localized Oral Cavity Medullary Carcinoma	16 860	384	53	70,0%
533	Skin Medullary Carcinoma (Stage I / Early Localized)	16 725	381	133	96,3%
534	Medullary Carcinoma of the Bone – Stage I / Early Localized	16 592	377	136	16,3%
535	Stage I / Early Localized Gallbladder Medullary Carcinoma	16 459	373	143	75,3%
536	Bile Duct Medullary Carcinoma (Stage I / Early Localized)	16 327	369	265	46,1%
537	Medullary Carcinoma of the Small Intestine – Stage I / Early Localized	16 197	366	129	16,9%
538	Stage I / Early Localized Anus Medullary Carcinoma	16 067	362	194	56,1%
539	Vagina Medullary Carcinoma (Stage I / Early Localized)	15 938	358	125	41,1%
540	Medullary Carcinoma of the Vulva – Stage I / Early Localized	15 811	355	66	84,7%
541	Stage I / Early Localized Testis Medullary Carcinoma	15 684	351	163	79,0%
542	Penis Medullary Carcinoma (Stage I / Early Localized)	15 559	348	85	79,9%
543	Medullary Carcinoma of the Adrenal Gland – Stage I / Early Localized	15 435	344	200	70,8%
544	Stage I / Early Localized Parathyroid Medullary Carcinoma	15 311	341	106	75,7%
545	Thymus Medullary Carcinoma (Stage I / Early Localized)	15 189	337	115	65,5%
546	Medullary Carcinoma of the Spleen – Stage I / Early Localized	15 067	334	150	64,1%
547	Stage I / Early Localized Nasopharynx Medullary Carcinoma	14 947	331	94	84,8%
548	Hypopharynx Medullary Carcinoma (Stage I / Early Localized)	14 827	327	207	37,7%
549	Medullary Carcinoma of the Oropharynx – Stage I / Early Localized	14 708	324	179	63,0%
550	Stage I / Early Localized Salivary Gland Medullary Carcinoma	14 591	321	62	47,0%
551	Appendix Medullary Carcinoma (Stage I / Early Localized)	14 474	318	32	63,4%
552	Medullary Carcinoma of the Peritoneum – Stage I / Early Localized	14 358	314	131	36,0%
553	Stage I / Early Localized Retroperitoneum Medullary Carcinoma	14 243	311	171	85,7%
554	Heart / Mediastinum Medullary Carcinoma (Stage I / Early Localized)	14 129	308	65	91,2%
555	Anaplastic Carcinoma of the Lung – Stage I / Early Localized	14 016	305	166	49,0%
556	Stage I / Early Localized Breast Anaplastic Carcinoma	13 904	302	93	55,5%
557	Colon Anaplastic Carcinoma (Stage I / Early Localized)	13 793	299	206	37,8%
558	Anaplastic Carcinoma of the Rectum – Stage I / Early Localized	13 683	296	188	32,2%
559	Stage I / Early Localized Stomach Anaplastic Carcinoma	13 573	293	195	62,7%
560	Pancreas Anaplastic Carcinoma (Stage I / Early Localized)	13 464	290	85	38,4%
561	Anaplastic Carcinoma of the Liver – Stage I / Early Localized	13 357	287	192	65,9%
562	Stage I / Early Localized Kidney Anaplastic Carcinoma	13 250	284	142	45,9%
563	Bladder Anaplastic Carcinoma (Stage I / Early Localized)	13 144	281	98	50,7%
564	Anaplastic Carcinoma of the Prostate – Stage I / Early Localized	13 039	279	89	20,2%
565	Stage I / Early Localized Ovary Anaplastic Carcinoma	12 934	276	87	81,8%
566	Uterus Anaplastic Carcinoma (Stage I / Early Localized)	12 831	273	97	69,5%
567	Anaplastic Carcinoma of the Cervix – Stage I / Early Localized	12 728	270	122	60,0%
568	Stage I / Early Localized Thyroid Anaplastic Carcinoma	12 626	268	82	76,4%
569	Brain Anaplastic Carcinoma (Stage I / Early Localized)	12 525	265	86	41,2%
570	Anaplastic Carcinoma of the Esophagus – Stage I / Early Localized	12 425	262	63	52,3%
571	Stage I / Early Localized Larynx Anaplastic Carcinoma	12 326	260	80	51,1%
572	Oral Cavity Anaplastic Carcinoma (Stage I / Early Localized)	12 227	257	119	85,3%
573	Anaplastic Carcinoma of the Skin – Stage I / Early Localized	12 129	254	68	94,9%
574	Stage I / Early Localized Bone Anaplastic Carcinoma	12 032	252	148	21,0%
575	Gallbladder Anaplastic Carcinoma (Stage I / Early Localized)	11 936	249	72	33,5%
576	Anaplastic Carcinoma of the Bile Duct – Stage I / Early Localized	11 841	247	67	85,4%
577	Stage I / Early Localized Small Intestine Anaplastic Carcinoma	11 746	244	130	11,2%
578	Anus Anaplastic Carcinoma (Stage I / Early Localized)	11 652	242	53	17,7%
579	Anaplastic Carcinoma of the Vagina – Stage I / Early Localized	11 559	240	46	72,0%
580	Stage I / Early Localized Vulva Anaplastic Carcinoma	11 466	237	160	93,6%
581	Testis Anaplastic Carcinoma (Stage I / Early Localized)	11 374	235	99	19,9%
582	Anaplastic Carcinoma of the Penis – Stage I / Early Localized	11 283	232	109	55,4%
583	Stage I / Early Localized Adrenal Gland Anaplastic Carcinoma	11 193	230	109	35,9%
584	Parathyroid Anaplastic Carcinoma (Stage I / Early Localized)	11 104	228	34	47,0%
585	Anaplastic Carcinoma of the Thymus – Stage I / Early Localized	11 015	225	34	96,8%
586	Stage I / Early Localized Spleen Anaplastic Carcinoma	10 927	223	147	79,3%
587	Nasopharynx Anaplastic Carcinoma (Stage I / Early Localized)	10 839	221	27	61,7%
588	Anaplastic Carcinoma of the Hypopharynx – Stage I / Early Localized	10 753	219	120	44,4%
589	Stage I / Early Localized Oropharynx Anaplastic Carcinoma	10 667	217	36	94,4%
590	Salivary Gland Anaplastic Carcinoma (Stage I / Early Localized)	10 581	214	94	13,1%
591	Anaplastic Carcinoma of the Appendix – Stage I / Early Localized	10 497	212	121	35,7%
592	Stage I / Early Localized Peritoneum Anaplastic Carcinoma	10 413	210	140	58,9%
593	Retroperitoneum Anaplastic Carcinoma (Stage I / Early Localized)	10 329	208	127	48,9%
594	Anaplastic Carcinoma of the Heart / Mediastinum – Stage I / Early Localized	10 247	206	139	46,7%
595	Stage I / Early Localized Lung Undifferentiated Carcinoma	10 165	204	35	66,0%
596	Breast Undifferentiated Carcinoma (Stage I / Early Localized)	10 083	202	143	25,2%
597	Undifferentiated Carcinoma of the Colon – Stage I / Early Localized	10 003	200	66	15,2%
598	Stage I / Early Localized Rectum Undifferentiated Carcinoma	9 923	198	73	60,4%
599	Stomach Undifferentiated Carcinoma (Stage I / Early Localized)	9 843	196	118	48,9%
600	Undifferentiated Carcinoma of the Pancreas – Stage I / Early Localized	9 765	194	94	78,5%
601	Stage I / Early Localized Liver Undifferentiated Carcinoma	9 686	192	50	78,2%
602	Kidney Undifferentiated Carcinoma (Stage I / Early Localized)	9 609	190	112	48,0%
603	Undifferentiated Carcinoma of the Bladder – Stage I / Early Localized	9 532	188	47	74,7%
604	Stage I / Early Localized Prostate Undifferentiated Carcinoma	9 456	186	77	24,0%
605	Ovary Undifferentiated Carcinoma (Stage I / Early Localized)	9 380	184	52	76,6%
606	Undifferentiated Carcinoma of the Uterus – Stage I / Early Localized	9 305	182	94	13,7%
607	Stage I / Early Localized Cervix Undifferentiated Carcinoma	9 231	181	26	51,1%
608	Thyroid Undifferentiated Carcinoma (Stage I / Early Localized)	9 157	179	23	44,6%
609	Undifferentiated Carcinoma of the Brain – Stage I / Early Localized	9 084	177	22	96,5%
610	Stage I / Early Localized Esophagus Undifferentiated Carcinoma	9 011	175	55	68,6%
611	Larynx Undifferentiated Carcinoma (Stage I / Early Localized)	8 939	174	44	29,8%
612	Undifferentiated Carcinoma of the Oral Cavity – Stage I / Early Localized	8 867	172	51	19,0%
613	Stage I / Early Localized Skin Undifferentiated Carcinoma	8 796	170	72	20,6%
614	Bone Undifferentiated Carcinoma (Stage I / Early Localized)	8 726	168	71	70,3%
615	Undifferentiated Carcinoma of the Gallbladder – Stage I / Early Localized	8 656	167	62	40,9%
616	Stage I / Early Localized Bile Duct Undifferentiated Carcinoma	8 587	165	95	22,8%
617	Small Intestine Undifferentiated Carcinoma (Stage I / Early Localized)	8 518	163	28	58,5%
618	Undifferentiated Carcinoma of the Anus – Stage I / Early Localized	8 450	162	83	44,6%
619	Stage I / Early Localized Vagina Undifferentiated Carcinoma	8 382	160	73	51,5%
620	Vulva Undifferentiated Carcinoma (Stage I / Early Localized)	8 315	158	31	76,4%
621	Undifferentiated Carcinoma of the Testis – Stage I / Early Localized	8 249	157	106	51,7%
622	Stage I / Early Localized Penis Undifferentiated Carcinoma	8 183	155	102	62,2%
623	Adrenal Gland Undifferentiated Carcinoma (Stage I / Early Localized)	8 117	154	73	35,7%
624	Undifferentiated Carcinoma of the Parathyroid – Stage I / Early Localized	8 052	152	107	57,0%
625	Stage I / Early Localized Thymus Undifferentiated Carcinoma	7 988	151	107	40,7%
626	Spleen Undifferentiated Carcinoma (Stage I / Early Localized)	7 924	149	101	72,8%
627	Undifferentiated Carcinoma of the Nasopharynx – Stage I / Early Localized	7 861	148	56	90,3%
628	Stage I / Early Localized Hypopharynx Undifferentiated Carcinoma	7 798	146	97	24,1%
629	Oropharynx Undifferentiated Carcinoma (Stage I / Early Localized)	7 735	145	53	87,5%
630	Undifferentiated Carcinoma of the Salivary Gland – Stage I / Early Localized	7 674	143	98	72,4%
631	Stage I / Early Localized Appendix Undifferentiated Carcinoma	7 612	142	30	21,6%
632	Peritoneum Undifferentiated Carcinoma (Stage I / Early Localized)	7 551	140	97	81,7%
633	Undifferentiated Carcinoma of the Retroperitoneum – Stage I / Early Localized	7 491	139	17	38,2%
634	Stage I / Early Localized Heart / Mediastinum Undifferentiated Carcinoma	7 431	138	37	94,5%
635	Lung Adenosquamous Carcinoma (Stage I / Early Localized)	7 371	136	71	82,6%
636	Adenosquamous Carcinoma of the Breast – Stage I / Early Localized	7 312	135	90	36,0%
637	Stage I / Early Localized Colon Adenosquamous Carcinoma	7 254	133	47	86,3%
638	Rectum Adenosquamous Carcinoma (Stage I / Early Localized)	7 196	132	65	91,6%
639	Adenosquamous Carcinoma of the Stomach – Stage I / Early Localized	7 138	131	11	95,7%
640	Stage I / Early Localized Pancreas Adenosquamous Carcinoma	7 081	130	27	64,8%
641	Liver Adenosquamous Carcinoma (Stage I / Early Localized)	7 025	128	36	32,8%
642	Adenosquamous Carcinoma of the Kidney – Stage I / Early Localized	6 968	127	89	83,1%
643	Stage I / Early Localized Bladder Adenosquamous Carcinoma	6 913	126	65	57,5%
644	Prostate Adenosquamous Carcinoma (Stage I / Early Localized)	6 857	124	58	14,7%
645	Adenosquamous Carcinoma of the Ovary – Stage I / Early Localized	6 802	123	76	60,5%
646	Stage I / Early Localized Uterus Adenosquamous Carcinoma	6 748	122	48	69,9%
647	Cervix Adenosquamous Carcinoma (Stage I / Early Localized)	6 694	121	63	16,4%
648	Adenosquamous Carcinoma of the Thyroid – Stage I / Early Localized	6 640	119	59	86,1%
649	Stage I / Early Localized Brain Adenosquamous Carcinoma	6 587	118	24	91,6%
650	Esophagus Adenosquamous Carcinoma (Stage I / Early Localized)	6 535	117	50	56,1%
651	Adenosquamous Carcinoma of the Larynx – Stage I / Early Localized	6 482	116	68	57,2%
652	Stage I / Early Localized Oral Cavity Adenosquamous Carcinoma	6 431	115	65	65,7%
653	Skin Adenosquamous Carcinoma (Stage I / Early Localized)	6 379	114	73	78,7%
654	Adenosquamous Carcinoma of the Bone – Stage I / Early Localized	6 328	112	40	91,3%
655	Stage I / Early Localized Gallbladder Adenosquamous Carcinoma	6 277	111	12	62,5%
656	Bile Duct Adenosquamous Carcinoma (Stage I / Early Localized)	6 227	110	42	85,6%
657	Adenosquamous Carcinoma of the Small Intestine – Stage I / Early Localized	6 177	109	41	21,3%
658	Stage I / Early Localized Anus Adenosquamous Carcinoma	6 128	108	71	85,1%
659	Vagina Adenosquamous Carcinoma (Stage I / Early Localized)	6 079	107	74	33,7%
660	Adenosquamous Carcinoma of the Vulva – Stage I / Early Localized	6 030	106	24	30,4%
661	Stage I / Early Localized Testis Adenosquamous Carcinoma	5 982	105	22	95,8%
662	Penis Adenosquamous Carcinoma (Stage I / Early Localized)	5 934	104	38	69,9%
663	Adenosquamous Carcinoma of the Adrenal Gland – Stage I / Early Localized	5 887	103	16	74,6%
664	Stage I / Early Localized Parathyroid Adenosquamous Carcinoma	5 840	102	42	41,2%
665	Thymus Adenosquamous Carcinoma (Stage I / Early Localized)	5 793	101	33	80,0%
666	Adenosquamous Carcinoma of the Spleen – Stage I / Early Localized	5 747	100	49	81,1%
667	Stage I / Early Localized Nasopharynx Adenosquamous Carcinoma	5 701	99	52	36,9%
668	Hypopharynx Adenosquamous Carcinoma (Stage I / Early Localized)	5 655	98	27	48,0%
669	Adenosquamous Carcinoma of the Oropharynx – Stage I / Early Localized	5 610	97	33	48,5%
670	Stage I / Early Localized Salivary Gland Adenosquamous Carcinoma	5 565	96	34	18,7%
671	Appendix Adenosquamous Carcinoma (Stage I / Early Localized)	5 520	95	30	42,6%
672	Adenosquamous Carcinoma of the Peritoneum – Stage I / Early Localized	5 476	94	20	57,8%
673	Stage I / Early Localized Retroperitoneum Adenosquamous Carcinoma	5 432	93	42	77,0%
674	Heart / Mediastinum Adenosquamous Carcinoma (Stage I / Early Localized)	5 389	92	63	33,5%
675	Leiomyosarcoma of the Lung – Stage I / Early Localized	5 346	91	25	72,4%
676	Stage I / Early Localized Breast Leiomyosarcoma	5 303	90	49	80,4%
677	Colon Leiomyosarcoma (Stage I / Early Localized)	5 261	89	55	39,4%
678	Leiomyosarcoma of the Rectum – Stage I / Early Localized	5 218	88	12	27,7%
679	Stage I / Early Localized Stomach Leiomyosarcoma	5 177	87	21	17,8%
680	Pancreas Leiomyosarcoma (Stage I / Early Localized)	5 135	86	16	73,1%
681	Leiomyosarcoma of the Liver – Stage I / Early Localized	5 094	86	19	37,6%
682	Stage I / Early Localized Kidney Leiomyosarcoma	5 053	85	28	83,4%
683	Bladder Leiomyosarcoma (Stage I / Early Localized)	5 013	84	10	34,6%
684	Leiomyosarcoma of the Prostate – Stage I / Early Localized	4 973	83	57	87,2%
685	Stage I / Early Localized Ovary Leiomyosarcoma	4 933	82	21	18,9%
686	Uterus Leiomyosarcoma (Stage I / Early Localized)	4 894	81	10	82,7%
687	Leiomyosarcoma of the Cervix – Stage I / Early Localized	4 854	81	46	39,9%
688	Stage I / Early Localized Thyroid Leiomyosarcoma	4 816	80	47	76,4%
689	Brain Leiomyosarcoma (Stage I / Early Localized)	4 777	79	51	55,0%
690	Leiomyosarcoma of the Esophagus – Stage I / Early Localized	4 739	78	43	47,0%
691	Stage I / Early Localized Larynx Leiomyosarcoma	4 701	77	12	70,0%
692	Oral Cavity Leiomyosarcoma (Stage I / Early Localized)	4 663	77	12	15,7%
693	Leiomyosarcoma of the Skin – Stage I / Early Localized	4 626	76	48	32,3%
694	Stage I / Early Localized Bone Leiomyosarcoma	4 589	75	21	60,6%
695	Gallbladder Leiomyosarcoma (Stage I / Early Localized)	4 552	74	20	30,4%
696	Leiomyosarcoma of the Bile Duct – Stage I / Early Localized	4 516	74	35	34,2%
697	Stage I / Early Localized Small Intestine Leiomyosarcoma	4 480	73	37	89,3%
698	Anus Leiomyosarcoma (Stage I / Early Localized)	4 444	72	31	34,5%
699	Leiomyosarcoma of the Vagina – Stage I / Early Localized	4 408	71	27	50,5%
700	Stage I / Early Localized Vulva Leiomyosarcoma	4 373	71	29	72,7%
701	Testis Leiomyosarcoma (Stage I / Early Localized)	4 338	70	38	76,9%
702	Leiomyosarcoma of the Penis – Stage I / Early Localized	4 303	69	11	80,1%
703	Stage I / Early Localized Adrenal Gland Leiomyosarcoma	4 269	69	23	26,4%
704	Parathyroid Leiomyosarcoma (Stage I / Early Localized)	4 235	68	47	64,2%
705	Leiomyosarcoma of the Thymus – Stage I / Early Localized	4 201	67	22	59,0%
706	Stage I / Early Localized Spleen Leiomyosarcoma	4 167	66	10	59,1%
707	Nasopharynx Leiomyosarcoma (Stage I / Early Localized)	4 134	66	10	87,0%
708	Leiomyosarcoma of the Hypopharynx – Stage I / Early Localized	4 101	65	45	14,7%
709	Stage I / Early Localized Oropharynx Leiomyosarcoma	4 068	64	17	22,3%
710	Salivary Gland Leiomyosarcoma (Stage I / Early Localized)	4 036	64	10	15,4%
711	Leiomyosarcoma of the Appendix – Stage I / Early Localized	4 003	63	10	92,2%
712	Stage I / Early Localized Peritoneum Leiomyosarcoma	3 971	63	22	15,4%
713	Retroperitoneum Leiomyosarcoma (Stage I / Early Localized)	3 939	62	34	62,1%
714	Leiomyosarcoma of the Heart / Mediastinum – Stage I / Early Localized	3 908	61	24	94,5%
715	Stage I / Early Localized Lung Liposarcoma	3 877	61	10	50,0%
716	Breast Liposarcoma (Stage I / Early Localized)	3 846	60	12	37,8%
717	Liposarcoma of the Colon – Stage I / Early Localized	3 815	59	41	52,1%
718	Stage I / Early Localized Rectum Liposarcoma	3 784	59	30	70,7%
719	Stomach Liposarcoma (Stage I / Early Localized)	3 754	58	10	47,2%
720	Liposarcoma of the Pancreas – Stage I / Early Localized	3 724	58	31	84,4%
721	Stage I / Early Localized Liver Liposarcoma	3 694	57	37	37,3%
722	Kidney Liposarcoma (Stage I / Early Localized)	3 665	57	13	18,2%
723	Liposarcoma of the Bladder – Stage I / Early Localized	3 635	56	10	13,4%
724	Stage I / Early Localized Prostate Liposarcoma	3 606	55	22	92,5%
725	Ovary Liposarcoma (Stage I / Early Localized)	3 577	55	10	37,3%
726	Liposarcoma of the Uterus – Stage I / Early Localized	3 549	54	26	11,3%
727	Stage I / Early Localized Cervix Liposarcoma	3 520	54	10	25,3%
728	Thyroid Liposarcoma (Stage I / Early Localized)	3 492	53	10	49,1%
729	Liposarcoma of the Brain – Stage I / Early Localized	3 464	53	10	48,1%
730	Stage I / Early Localized Esophagus Liposarcoma	3 437	52	10	89,1%
731	Larynx Liposarcoma (Stage I / Early Localized)	3 409	52	10	61,9%
732	Liposarcoma of the Oral Cavity – Stage I / Early Localized	3 382	51	33	18,0%
733	Stage I / Early Localized Skin Liposarcoma	3 355	51	36	47,0%
734	Bone Liposarcoma (Stage I / Early Localized)	3 328	50	10	71,6%
735	Liposarcoma of the Gallbladder – Stage I / Early Localized	3 301	50	29	77,7%
736	Stage I / Early Localized Bile Duct Liposarcoma	3 275	50	31	49,6%
737	Small Intestine Liposarcoma (Stage I / Early Localized)	3 249	50	10	40,2%
738	Liposarcoma of the Anus – Stage I / Early Localized	3 223	50	19	73,1%
739	Stage I / Early Localized Vagina Liposarcoma	3 197	50	22	64,2%
740	Vulva Liposarcoma (Stage I / Early Localized)	3 171	50	10	83,9%
741	Liposarcoma of the Testis – Stage I / Early Localized	3 146	50	10	86,5%
742	Stage I / Early Localized Penis Liposarcoma	3 121	50	10	53,3%
743	Adrenal Gland Liposarcoma (Stage I / Early Localized)	3 096	50	30	96,1%
744	Liposarcoma of the Parathyroid – Stage I / Early Localized	3 071	50	25	19,7%
745	Stage I / Early Localized Thymus Liposarcoma	3 046	50	17	42,6%
746	Spleen Liposarcoma (Stage I / Early Localized)	3 022	50	31	22,6%
747	Liposarcoma of the Nasopharynx – Stage I / Early Localized	2 998	50	22	86,4%
748	Stage I / Early Localized Hypopharynx Liposarcoma	2 974	50	23	89,7%
749	Oropharynx Liposarcoma (Stage I / Early Localized)	2 950	50	35	90,6%
750	Liposarcoma of the Salivary Gland – Stage I / Early Localized	2 927	50	25	51,5%
751	Stage I / Early Localized Appendix Liposarcoma	2 903	50	14	33,3%
752	Peritoneum Liposarcoma (Stage I / Early Localized)	2 880	50	32	15,9%
753	Liposarcoma of the Retroperitoneum – Stage I / Early Localized	2 857	50	16	94,1%
754	Stage I / Early Localized Heart / Mediastinum Liposarcoma	2 834	50	30	19,3%
755	Lung Rhabdomyosarcoma (Stage I / Early Localized)	2 811	50	19	78,6%
756	Rhabdomyosarcoma of the Breast – Stage I / Early Localized	2 789	50	20	95,9%
757	Stage I / Early Localized Colon Rhabdomyosarcoma	2 766	50	30	61,0%
758	Rectum Rhabdomyosarcoma (Stage I / Early Localized)	2 744	50	10	58,2%
759	Rhabdomyosarcoma of the Stomach – Stage I / Early Localized	2 722	50	10	33,9%
760	Stage I / Early Localized Pancreas Rhabdomyosarcoma	2 701	50	18	95,7%
761	Liver Rhabdomyosarcoma (Stage I / Early Localized)	2 679	50	25	69,6%
762	Rhabdomyosarcoma of the Kidney – Stage I / Early Localized	2 658	50	10	33,8%
763	Stage I / Early Localized Bladder Rhabdomyosarcoma	2 636	50	30	75,4%
764	Prostate Rhabdomyosarcoma (Stage I / Early Localized)	2 615	50	17	80,5%
765	Rhabdomyosarcoma of the Ovary – Stage I / Early Localized	2 594	50	20	25,6%
766	Stage I / Early Localized Uterus Rhabdomyosarcoma	2 574	50	10	67,7%
767	Cervix Rhabdomyosarcoma (Stage I / Early Localized)	2 553	50	23	95,4%
768	Rhabdomyosarcoma of the Thyroid – Stage I / Early Localized	2 532	50	10	73,8%
769	Stage I / Early Localized Brain Rhabdomyosarcoma	2 512	50	26	22,5%
770	Esophagus Rhabdomyosarcoma (Stage I / Early Localized)	2 492	50	27	24,3%
771	Rhabdomyosarcoma of the Larynx – Stage I / Early Localized	2 472	50	10	75,2%
772	Stage I / Early Localized Oral Cavity Rhabdomyosarcoma	2 452	50	10	25,0%
773	Skin Rhabdomyosarcoma (Stage I / Early Localized)	2 433	50	11	51,2%
774	Rhabdomyosarcoma of the Bone – Stage I / Early Localized	2 413	50	35	78,4%
775	Stage I / Early Localized Gallbladder Rhabdomyosarcoma	2 394	50	25	62,1%
776	Bile Duct Rhabdomyosarcoma (Stage I / Early Localized)	2 375	50	26	14,8%
777	Rhabdomyosarcoma of the Small Intestine – Stage I / Early Localized	2 356	50	10	96,9%
778	Stage I / Early Localized Anus Rhabdomyosarcoma	2 337	50	10	95,8%
779	Vagina Rhabdomyosarcoma (Stage I / Early Localized)	2 318	50	22	58,7%
780	Rhabdomyosarcoma of the Vulva – Stage I / Early Localized	2 300	50	10	21,5%
781	Stage I / Early Localized Testis Rhabdomyosarcoma	2 281	50	10	89,3%
782	Penis Rhabdomyosarcoma (Stage I / Early Localized)	2 263	50	10	20,1%
783	Rhabdomyosarcoma of the Adrenal Gland – Stage I / Early Localized	2 245	50	11	64,8%
784	Stage I / Early Localized Parathyroid Rhabdomyosarcoma	2 227	50	14	26,3%
785	Thymus Rhabdomyosarcoma (Stage I / Early Localized)	2 209	50	22	87,4%
786	Rhabdomyosarcoma of the Spleen – Stage I / Early Localized	2 192	50	17	92,3%
787	Stage I / Early Localized Nasopharynx Rhabdomyosarcoma	2 174	50	35	51,5%
788	Hypopharynx Rhabdomyosarcoma (Stage I / Early Localized)	2 157	50	34	80,2%
789	Rhabdomyosarcoma of the Oropharynx – Stage I / Early Localized	2 139	50	33	45,0%
790	Stage I / Early Localized Salivary Gland Rhabdomyosarcoma	2 122	50	10	55,0%
791	Appendix Rhabdomyosarcoma (Stage I / Early Localized)	2 105	50	10	84,6%
792	Rhabdomyosarcoma of the Peritoneum – Stage I / Early Localized	2 088	50	16	20,4%
793	Stage I / Early Localized Retroperitoneum Rhabdomyosarcoma	2 072	50	10	56,5%
794	Heart / Mediastinum Rhabdomyosarcoma (Stage I / Early Localized)	2 055	50	15	16,2%
795	Angiosarcoma of the Lung – Stage I / Early Localized	2 039	50	10	25,3%
796	Stage I / Early Localized Breast Angiosarcoma	2 022	50	10	45,8%
797	Colon Angiosarcoma (Stage I / Early Localized)	2 006	50	28	60,9%
798	Angiosarcoma of the Rectum – Stage I / Early Localized	1 990	50	23	39,8%
799	Stage I / Early Localized Stomach Angiosarcoma	1 974	50	12	21,9%
800	Pancreas Angiosarcoma (Stage I / Early Localized)	1 958	50	13	45,0%
801	Angiosarcoma of the Liver – Stage I / Early Localized	1 943	50	14	38,6%
802	Stage I / Early Localized Kidney Angiosarcoma	1 927	50	10	85,7%
803	Bladder Angiosarcoma (Stage I / Early Localized)	1 912	50	27	21,2%
804	Angiosarcoma of the Prostate – Stage I / Early Localized	1 896	50	27	95,4%
805	Stage I / Early Localized Ovary Angiosarcoma	1 881	50	10	27,7%
806	Uterus Angiosarcoma (Stage I / Early Localized)	1 866	50	32	52,7%
807	Angiosarcoma of the Cervix – Stage I / Early Localized	1 851	50	10	72,7%
808	Stage I / Early Localized Thyroid Angiosarcoma	1 836	50	32	51,8%
809	Brain Angiosarcoma (Stage I / Early Localized)	1 822	50	34	21,7%
810	Angiosarcoma of the Esophagus – Stage I / Early Localized	1 807	50	28	84,9%
811	Stage I / Early Localized Larynx Angiosarcoma	1 793	50	11	65,2%
812	Oral Cavity Angiosarcoma (Stage I / Early Localized)	1 778	50	10	40,1%
813	Angiosarcoma of the Skin – Stage I / Early Localized	1 764	50	15	62,1%
814	Stage I / Early Localized Bone Angiosarcoma	1 750	50	21	46,0%
815	Gallbladder Angiosarcoma (Stage I / Early Localized)	1 736	50	21	77,4%
816	Angiosarcoma of the Bile Duct – Stage I / Early Localized	1 722	50	14	29,7%
817	Stage I / Early Localized Small Intestine Angiosarcoma	1 708	50	16	14,6%
818	Anus Angiosarcoma (Stage I / Early Localized)	1 695	50	33	91,2%
819	Angiosarcoma of the Vagina – Stage I / Early Localized	1 681	50	10	41,2%
820	Stage I / Early Localized Vulva Angiosarcoma	1 668	50	10	41,5%
821	Testis Angiosarcoma (Stage I / Early Localized)	1 654	50	10	42,6%
822	Angiosarcoma of the Penis – Stage I / Early Localized	1 641	50	26	18,2%
823	Stage I / Early Localized Adrenal Gland Angiosarcoma	1 628	50	21	22,8%
824	Parathyroid Angiosarcoma (Stage I / Early Localized)	1 615	50	24	81,6%
825	Angiosarcoma of the Thymus – Stage I / Early Localized	1 602	50	29	95,8%
826	Stage I / Early Localized Spleen Angiosarcoma	1 589	50	13	59,8%
827	Nasopharynx Angiosarcoma (Stage I / Early Localized)	1 576	50	31	22,5%
828	Angiosarcoma of the Hypopharynx – Stage I / Early Localized	1 564	50	10	54,8%
829	Stage I / Early Localized Oropharynx Angiosarcoma	1 551	50	27	16,7%
830	Salivary Gland Angiosarcoma (Stage I / Early Localized)	1 539	50	11	79,8%
831	Angiosarcoma of the Appendix – Stage I / Early Localized	1 527	50	27	88,8%
832	Stage I / Early Localized Peritoneum Angiosarcoma	1 514	50	10	26,0%
833	Retroperitoneum Angiosarcoma (Stage I / Early Localized)	1 502	50	10	80,7%
834	Angiosarcoma of the Heart / Mediastinum – Stage I / Early Localized	1 490	50	20	68,2%
835	Stage I / Early Localized Lung Synovial Sarcoma	1 478	50	16	53,0%
836	Breast Synovial Sarcoma (Stage I / Early Localized)	1 466	50	32	78,9%
837	Synovial Sarcoma of the Colon – Stage I / Early Localized	1 455	50	18	45,0%
838	Stage I / Early Localized Rectum Synovial Sarcoma	1 443	50	13	12,0%
839	Stomach Synovial Sarcoma (Stage I / Early Localized)	1 432	50	13	25,7%
840	Synovial Sarcoma of the Pancreas – Stage I / Early Localized	1 420	50	30	55,7%
841	Stage I / Early Localized Liver Synovial Sarcoma	1 409	50	14	69,4%
842	Kidney Synovial Sarcoma (Stage I / Early Localized)	1 397	50	12	76,0%
843	Synovial Sarcoma of the Bladder – Stage I / Early Localized	1 386	50	17	82,8%
844	Stage I / Early Localized Prostate Synovial Sarcoma	1 375	50	10	71,7%
845	Ovary Synovial Sarcoma (Stage I / Early Localized)	1 364	50	23	88,2%
846	Synovial Sarcoma of the Uterus – Stage I / Early Localized	1 353	50	24	53,2%
847	Stage I / Early Localized Cervix Synovial Sarcoma	1 342	50	12	65,4%
848	Thyroid Synovial Sarcoma (Stage I / Early Localized)	1 332	50	16	14,4%
849	Synovial Sarcoma of the Brain – Stage I / Early Localized	1 321	50	30	90,2%
850	Stage I / Early Localized Esophagus Synovial Sarcoma	1 310	50	18	30,3%
851	Larynx Synovial Sarcoma (Stage I / Early Localized)	1 300	50	11	73,3%
852	Synovial Sarcoma of the Oral Cavity – Stage I / Early Localized	1 290	50	25	40,3%
853	Stage I / Early Localized Skin Synovial Sarcoma	1 279	50	13	44,9%
854	Bone Synovial Sarcoma (Stage I / Early Localized)	1 269	50	34	11,9%
855	Synovial Sarcoma of the Gallbladder – Stage I / Early Localized	1 259	50	17	40,0%
856	Stage I / Early Localized Bile Duct Synovial Sarcoma	1 249	50	12	29,9%
857	Small Intestine Synovial Sarcoma (Stage I / Early Localized)	1 239	50	10	51,0%
858	Synovial Sarcoma of the Anus – Stage I / Early Localized	1 229	50	29	68,9%
859	Stage I / Early Localized Vagina Synovial Sarcoma	1 219	50	10	57,8%
860	Vulva Synovial Sarcoma (Stage I / Early Localized)	1 209	50	19	20,4%
861	Synovial Sarcoma of the Testis – Stage I / Early Localized	1 200	50	23	90,3%
862	Stage I / Early Localized Penis Synovial Sarcoma	1 190	50	16	32,9%
863	Adrenal Gland Synovial Sarcoma (Stage I / Early Localized)	1 180	50	16	62,4%
864	Synovial Sarcoma of the Parathyroid – Stage I / Early Localized	1 171	50	29	14,9%
865	Stage I / Early Localized Thymus Synovial Sarcoma	1 162	50	11	26,4%
866	Spleen Synovial Sarcoma (Stage I / Early Localized)	1 152	50	14	57,4%
867	Synovial Sarcoma of the Nasopharynx – Stage I / Early Localized	1 143	50	30	90,0%
868	Stage I / Early Localized Hypopharynx Synovial Sarcoma	1 134	50	30	44,5%
869	Oropharynx Synovial Sarcoma (Stage I / Early Localized)	1 125	50	25	11,4%
870	Synovial Sarcoma of the Salivary Gland – Stage I / Early Localized	1 116	50	14	54,3%
871	Stage I / Early Localized Appendix Synovial Sarcoma	1 107	50	34	41,4%
872	Peritoneum Synovial Sarcoma (Stage I / Early Localized)	1 098	50	17	37,0%
873	Synovial Sarcoma of the Retroperitoneum – Stage I / Early Localized	1 089	50	10	59,4%
874	Stage I / Early Localized Heart / Mediastinum Synovial Sarcoma	1 081	50	10	67,9%
875	Lung Fibrosarcoma (Stage I / Early Localized)	1 072	50	32	60,2%
876	Fibrosarcoma of the Breast – Stage I / Early Localized	1 063	50	10	26,5%
877	Stage I / Early Localized Colon Fibrosarcoma	1 055	50	22	56,8%
878	Rectum Fibrosarcoma (Stage I / Early Localized)	1 046	50	18	60,3%
879	Fibrosarcoma of the Stomach – Stage I / Early Localized	1 038	50	11	89,4%
880	Stage I / Early Localized Pancreas Fibrosarcoma	1 030	50	26	53,8%
881	Liver Fibrosarcoma (Stage I / Early Localized)	1 022	50	10	13,2%
882	Fibrosarcoma of the Kidney – Stage I / Early Localized	1 013	50	22	62,5%
883	Stage I / Early Localized Bladder Fibrosarcoma	1 005	50	19	68,5%
884	Prostate Fibrosarcoma (Stage I / Early Localized)	997	50	10	76,1%
885	Fibrosarcoma of the Ovary – Stage I / Early Localized	989	50	29	25,4%
886	Stage I / Early Localized Uterus Fibrosarcoma	981	50	10	53,4%
887	Cervix Fibrosarcoma (Stage I / Early Localized)	973	50	34	65,0%
888	Fibrosarcoma of the Thyroid – Stage I / Early Localized	966	50	29	93,5%
889	Stage I / Early Localized Brain Fibrosarcoma	958	50	10	64,1%
890	Esophagus Fibrosarcoma (Stage I / Early Localized)	950	50	12	27,0%
891	Fibrosarcoma of the Larynx – Stage I / Early Localized	943	50	19	23,3%
892	Stage I / Early Localized Oral Cavity Fibrosarcoma	935	50	26	74,1%
893	Skin Fibrosarcoma (Stage I / Early Localized)	928	50	29	34,8%
894	Fibrosarcoma of the Bone – Stage I / Early Localized	920	50	12	16,4%
895	Stage I / Early Localized Gallbladder Fibrosarcoma	913	50	18	48,8%
896	Bile Duct Fibrosarcoma (Stage I / Early Localized)	905	50	17	80,1%
897	Fibrosarcoma of the Small Intestine – Stage I / Early Localized	898	50	12	25,2%
898	Stage I / Early Localized Anus Fibrosarcoma	891	50	10	48,1%
899	Vagina Fibrosarcoma (Stage I / Early Localized)	884	50	19	48,8%
900	Fibrosarcoma of the Vulva – Stage I / Early Localized	877	50	23	18,3%
901	Stage I / Early Localized Testis Fibrosarcoma	870	50	10	43,0%
902	Penis Fibrosarcoma (Stage I / Early Localized)	863	50	34	84,9%
903	Fibrosarcoma of the Adrenal Gland – Stage I / Early Localized	856	50	28	35,9%
904	Stage I / Early Localized Parathyroid Fibrosarcoma	849	50	18	78,9%
905	Thymus Fibrosarcoma (Stage I / Early Localized)	842	50	35	44,9%
906	Fibrosarcoma of the Spleen – Stage I / Early Localized	836	50	10	41,2%
907	Stage I / Early Localized Nasopharynx Fibrosarcoma	829	50	10	56,7%
908	Hypopharynx Fibrosarcoma (Stage I / Early Localized)	822	50	22	14,0%
909	Fibrosarcoma of the Oropharynx – Stage I / Early Localized	816	50	10	25,5%
910	Stage I / Early Localized Salivary Gland Fibrosarcoma	809	50	10	48,2%
911	Appendix Fibrosarcoma (Stage I / Early Localized)	803	50	16	46,8%
912	Fibrosarcoma of the Peritoneum – Stage I / Early Localized	796	50	22	95,0%
913	Stage I / Early Localized Retroperitoneum Fibrosarcoma	790	50	10	82,8%
914	Heart / Mediastinum Fibrosarcoma (Stage I / Early Localized)	784	50	11	27,2%
915	Ewing Sarcoma of the Lung – Stage I / Early Localized	777	50	28	25,8%
916	Stage I / Early Localized Breast Ewing Sarcoma	771	50	22	74,9%
917	Colon Ewing Sarcoma (Stage I / Early Localized)	765	50	19	42,9%
918	Ewing Sarcoma of the Rectum – Stage I / Early Localized	759	50	10	93,8%
919	Stage I / Early Localized Stomach Ewing Sarcoma	753	50	10	75,4%
920	Pancreas Ewing Sarcoma (Stage I / Early Localized)	747	50	23	23,9%
921	Ewing Sarcoma of the Liver – Stage I / Early Localized	741	50	10	53,2%
922	Stage I / Early Localized Kidney Ewing Sarcoma	735	50	10	44,1%
923	Bladder Ewing Sarcoma (Stage I / Early Localized)	729	50	14	59,9%
924	Ewing Sarcoma of the Prostate – Stage I / Early Localized	723	50	10	19,4%
925	Stage I / Early Localized Ovary Ewing Sarcoma	717	50	26	29,7%
926	Uterus Ewing Sarcoma (Stage I / Early Localized)	711	50	14	48,0%
927	Ewing Sarcoma of the Cervix – Stage I / Early Localized	706	50	29	71,9%
928	Stage I / Early Localized Thyroid Ewing Sarcoma	700	50	32	33,2%
929	Brain Ewing Sarcoma (Stage I / Early Localized)	695	50	10	84,8%
930	Ewing Sarcoma of the Esophagus – Stage I / Early Localized	689	50	10	43,2%
931	Stage I / Early Localized Larynx Ewing Sarcoma	683	50	34	35,7%
932	Oral Cavity Ewing Sarcoma (Stage I / Early Localized)	678	50	10	88,8%
933	Ewing Sarcoma of the Skin – Stage I / Early Localized	673	50	17	42,0%
934	Stage I / Early Localized Bone Ewing Sarcoma	667	50	24	35,5%
935	Gallbladder Ewing Sarcoma (Stage I / Early Localized)	662	50	27	89,9%
936	Ewing Sarcoma of the Bile Duct – Stage I / Early Localized	657	50	10	65,3%
937	Stage I / Early Localized Small Intestine Ewing Sarcoma	651	50	26	38,8%
938	Anus Ewing Sarcoma (Stage I / Early Localized)	646	50	32	57,7%
939	Ewing Sarcoma of the Vagina – Stage I / Early Localized	641	50	35	20,6%
940	Stage I / Early Localized Vulva Ewing Sarcoma	636	50	29	16,5%
941	Testis Ewing Sarcoma (Stage I / Early Localized)	631	50	29	47,8%
942	Ewing Sarcoma of the Penis – Stage I / Early Localized	626	50	12	69,7%
943	Stage I / Early Localized Adrenal Gland Ewing Sarcoma	621	50	21	82,6%
944	Parathyroid Ewing Sarcoma (Stage I / Early Localized)	616	50	32	55,0%
945	Ewing Sarcoma of the Thymus – Stage I / Early Localized	611	50	32	63,4%
946	Stage I / Early Localized Spleen Ewing Sarcoma	606	50	30	77,9%
947	Nasopharynx Ewing Sarcoma (Stage I / Early Localized)	601	50	33	47,2%
948	Ewing Sarcoma of the Hypopharynx – Stage I / Early Localized	596	50	33	12,3%
949	Stage I / Early Localized Oropharynx Ewing Sarcoma	591	50	10	60,5%
950	Salivary Gland Ewing Sarcoma (Stage I / Early Localized)	587	50	34	82,5%
951	Ewing Sarcoma of the Appendix – Stage I / Early Localized	582	50	26	92,3%
952	Stage I / Early Localized Peritoneum Ewing Sarcoma	577	50	34	37,5%
953	Retroperitoneum Ewing Sarcoma (Stage I / Early Localized)	573	50	10	19,8%
954	Ewing Sarcoma of the Heart / Mediastinum – Stage I / Early Localized	568	50	15	53,0%
955	Stage I / Early Localized Lung Osteosarcoma	564	50	27	32,3%
956	Breast Osteosarcoma (Stage I / Early Localized)	559	50	24	22,5%
957	Osteosarcoma of the Colon – Stage I / Early Localized	555	50	10	68,5%
958	Stage I / Early Localized Rectum Osteosarcoma	550	50	15	60,2%
959	Stomach Osteosarcoma (Stage I / Early Localized)	546	50	27	84,4%
960	Osteosarcoma of the Pancreas – Stage I / Early Localized	541	50	23	83,0%
961	Stage I / Early Localized Liver Osteosarcoma	537	50	34	83,4%
962	Kidney Osteosarcoma (Stage I / Early Localized)	533	50	21	54,3%
963	Osteosarcoma of the Bladder – Stage I / Early Localized	528	50	30	74,4%
964	Stage I / Early Localized Prostate Osteosarcoma	524	50	13	62,9%
965	Ovary Osteosarcoma (Stage I / Early Localized)	520	50	11	17,5%
966	Osteosarcoma of the Uterus – Stage I / Early Localized	516	50	13	30,0%
967	Stage I / Early Localized Cervix Osteosarcoma	512	50	24	29,5%
968	Thyroid Osteosarcoma (Stage I / Early Localized)	508	50	16	59,7%
969	Osteosarcoma of the Brain – Stage I / Early Localized	504	50	18	38,4%
970	Stage I / Early Localized Esophagus Osteosarcoma	500	50	35	46,9%
971	Larynx Osteosarcoma (Stage I / Early Localized)	496	50	14	92,4%
972	Osteosarcoma of the Oral Cavity – Stage I / Early Localized	492	50	10	50,7%
973	Stage I / Early Localized Skin Osteosarcoma	488	50	12	72,8%
974	Bone Osteosarcoma (Stage I / Early Localized)	484	50	10	61,1%
975	Osteosarcoma of the Gallbladder – Stage I / Early Localized	480	50	35	54,1%
976	Stage I / Early Localized Bile Duct Osteosarcoma	476	50	27	42,8%
977	Small Intestine Osteosarcoma (Stage I / Early Localized)	472	50	20	41,4%
978	Osteosarcoma of the Anus – Stage I / Early Localized	468	50	17	80,5%
979	Stage I / Early Localized Vagina Osteosarcoma	465	50	10	39,2%
980	Vulva Osteosarcoma (Stage I / Early Localized)	461	50	21	38,8%
981	Osteosarcoma of the Testis – Stage I / Early Localized	457	50	28	17,5%
982	Stage I / Early Localized Penis Osteosarcoma	454	50	20	94,9%
983	Adrenal Gland Osteosarcoma (Stage I / Early Localized)	450	50	26	33,5%
984	Osteosarcoma of the Parathyroid – Stage I / Early Localized	446	50	24	45,3%
985	Stage I / Early Localized Thymus Osteosarcoma	443	50	10	53,6%
986	Spleen Osteosarcoma (Stage I / Early Localized)	439	50	15	46,3%
987	Osteosarcoma of the Nasopharynx – Stage I / Early Localized	436	50	26	24,6%
988	Stage I / Early Localized Hypopharynx Osteosarcoma	432	50	24	66,5%
989	Oropharynx Osteosarcoma (Stage I / Early Localized)	429	50	21	21,4%
990	Osteosarcoma of the Salivary Gland – Stage I / Early Localized	425	50	13	29,0%
991	Stage I / Early Localized Appendix Osteosarcoma	422	50	10	63,6%
992	Peritoneum Osteosarcoma (Stage I / Early Localized)	419	50	33	90,4%
993	Osteosarcoma of the Retroperitoneum – Stage I / Early Localized	415	50	11	13,4%
994	Stage I / Early Localized Heart / Mediastinum Osteosarcoma	412	50	12	49,8%
995	Lung Chondrosarcoma (Stage I / Early Localized)	409	50	16	68,9%
996	Chondrosarcoma of the Breast – Stage I / Early Localized	405	50	29	55,7%
997	Stage I / Early Localized Colon Chondrosarcoma	402	50	16	59,8%
998	Rectum Chondrosarcoma (Stage I / Early Localized)	399	50	21	37,5%
999	Chondrosarcoma of the Stomach – Stage I / Early Localized	396	50	29	70,9%
1000	Stage I / Early Localized Pancreas Chondrosarcoma	392	50	10	48,1%

Key Points:

• Lung and bronchus cancer is by far the leading cause of cancer death in the U.S., responsible for about 20% of all cancer deaths.
• Lung, colorectal, pancreatic, and breast cancers are responsible for nearly 50% of all cancer deaths.
• The overall cancer mortality rate has declined by 34% since 1991, largely due to reductions in smoking, earlier detection, and improved treatments.

📝 Summary

This data, based on the American Cancer Society’s Cancer Statistics, 2026 report, highlights the most significant cancer burdens in the United States. While incidence is dominated by prostate and breast cancers, mortality is overwhelmingly driven by lung cancer. The continued decline in overall cancer death rates reflects decades of progress in prevention, screening, and treatment.

For the most current and detailed cancer statistics, including historical trends and demographic breakdowns, the following sources are authoritative:

Centers for Disease Control and Prevention (CDC): Publishes the official federal statistics on cancer incidence and mortality.

American Cancer Society (ACS): Publishes the annual “Cancer Statistics” report and “Cancer Facts & Figures.”

National Cancer Institute (NCI) SEER Program: Provides population-based cancer statistics.